<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Neurol</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Neurol</journal-id>
<journal-id journal-id-type="publisher-id">Front. Neurol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Neurology</journal-title>
</journal-title-group>
<issn pub-type="epub">1664-2295</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29770119</article-id>
<article-id pub-id-type="pmc">5941986</article-id>
<article-id pub-id-type="doi">10.3389/fneur.2018.00303</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Core Clinical Phenotypes in Myotonic Dystrophies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wenninger</surname>
<given-names>Stephan</given-names>
</name>
<xref ref-type="corresp" rid="fn001">*</xref>
<uri xlink:href="https://frontiersin.org/people/u/537345" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Montagnese</surname>
<given-names>Federica</given-names>
</name>
<uri xlink:href="https://frontiersin.org/people/u/546939" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schoser</surname>
<given-names>Benedikt</given-names>
</name>
<uri xlink:href="https://frontiersin.org/people/u/462009" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff><institution>Friedrich-Baur-Institute, Klinikum der Universität München</institution>, <addr-line>Munich</addr-line>, <country>Germany</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Edoardo Malfatti, INSERM UMRS974 Institut de Myologie, France</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Massimiliano Filosto, Asst degli Spedali Civili di Brescia, Italy; Rosanna Cardani, Policlinico San Donato (IRCCS), Italy</p>
</fn>
<corresp id="fn001">*Correspondence: Stephan Wenninger, <email>stephan.wenninger@med.uni-muenchen.de</email></corresp>
<fn fn-type="other" id="fn002">
<p>Specialty section: This article was submitted to Neuromuscular Diseases, a section of the journal Frontiers in Neurology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>02</day>
<month>5</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>9</volume>
<elocation-id>303</elocation-id>
<history>
<date date-type="received">
<day>09</day>
<month>3</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>4</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018 Wenninger, Montagnese and Schoser.</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>Wenninger, Montagnese and Schoser</copyright-holder>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Myotonic dystrophy type 1 (DM1) and type 2 (DM2) represent the most frequent multisystemic muscular dystrophies in adulthood. They are progressive, autosomal dominant diseases caused by an abnormal expansion of an unstable nucleotide repeat located in the non-coding region of their respective genes DMPK for DM1 and CNBP in DM2. Clinically, these multisystemic disorders are characterized by a high variability of muscular and extramuscular symptoms, often causing a delay in diagnosis. For both subtypes, many symptoms overlap, but some differences allow their clinical distinction. This article highlights the clinical core features of myotonic dystrophies, thus facilitating their early recognition and diagnosis. Particular attention will be given to signs and symptoms of muscular involvement, to issues related to respiratory impairment, and to the multiorgan involvement. This article is part of a Special Issue entitled “Beyond Borders: Myotonic Dystrophies—A European Perception.”</p>
</abstract>
<kwd-group>
<kwd>myotonic dystrophies</kwd>
<kwd>DM1</kwd>
<kwd>DM2</kwd>
<kwd>phenotypes</kwd>
<kwd>myotonia</kwd>
<kwd>sleep disorders</kwd>
<kwd>repeat expansion diseases</kwd>
</kwd-group>
<counts>
<fig-count count="2"></fig-count>
<table-count count="2"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="108"></ref-count>
<page-count count="9"></page-count>
<word-count count="7902"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="introduction">
<title>Introduction</title>
<p>The genetic background of myotonic dystrophies type 1 and 2 (DM1 and DM2) is due to repeat expansions of unstable nucleotides in untranslated DNA regions causing mis-splicing of mRNAs, which affects almost all cells and organs of the human body. This sum of alterations leads to an extremely heterogeneous phenotype with musltisystemic involvement. Many findings and symptoms of DM1 and DM2 overlap, but important differences usually allow their prompt clinical distinction (Table <xref ref-type="table" rid="T2">2</xref>). Both types of myotonic dystrophies represent the most common inherited muscle disorders in adulthood with regional variations in prevalence and incidence. In general, DM1 occurs more frequently than DM2, with some exeptions in northern and mid European countries such as Finland, Germany, and Czech Republic, where DM1 and DM2 are almost equally represented. Table <xref ref-type="table" rid="T1">1</xref> provides a useful summary of the country-specific prevalences (<xref ref-type="bibr" rid="B1">1</xref>–<xref ref-type="bibr" rid="B4">4</xref>).</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>Country-specific prevalences of DM1 and DM2.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">Country</th>
<th align="center" colspan="1" rowspan="1" valign="top">Disease</th>
<th align="center" colspan="1" rowspan="1" valign="top">Prevalence (×10<sup>5</sup>)</th>
<th align="center" colspan="1" rowspan="1" valign="top">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Croatia</td>
<td align="center" colspan="1" rowspan="1" valign="top">DMs</td>
<td align="center" colspan="1" rowspan="1" valign="top">18.1</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B5">5</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Czech Republic</td>
<td align="center" colspan="1" rowspan="1" valign="top">DM2</td>
<td align="center" colspan="1" rowspan="1" valign="top">DM2 &gt; DM1</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B6">6</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Finland</td>
<td align="center" colspan="1" rowspan="1" valign="top">DM2</td>
<td align="center" colspan="1" rowspan="1" valign="top">10</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B7">7</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Finland</td>
<td align="center" colspan="1" rowspan="1" valign="top">DM2</td>
<td align="center" colspan="1" rowspan="1" valign="top">54</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B8">8</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Germany</td>
<td align="center" colspan="1" rowspan="1" valign="top">DM2</td>
<td align="center" colspan="1" rowspan="1" valign="top">DM1 = DM2</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B9">9</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Israel</td>
<td align="center" colspan="1" rowspan="1" valign="top">DM1</td>
<td align="center" colspan="1" rowspan="1" valign="top">15.7</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B10">10</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Italy</td>
<td align="center" colspan="1" rowspan="1" valign="top">DMs</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.1</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B11">11</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Italy</td>
<td align="center" colspan="1" rowspan="1" valign="top">DM1</td>
<td align="center" colspan="1" rowspan="1" valign="top">9.3</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B12">12</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Italy</td>
<td align="center" colspan="1" rowspan="1" valign="top">DM2</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.9–1</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B13">13</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Italy</td>
<td align="center" colspan="1" rowspan="1" valign="top">DM1</td>
<td align="center" colspan="1" rowspan="1" valign="top">9.6–11.7</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B13">13</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Japan</td>
<td align="center" colspan="1" rowspan="1" valign="top">DMs</td>
<td align="center" colspan="1" rowspan="1" valign="top">9.1</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B14">14</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Spain, Mallorca</td>
<td align="center" colspan="1" rowspan="1" valign="top">DMs</td>
<td align="center" colspan="1" rowspan="1" valign="top">10.8</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B15">15</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">New Zeland, Otago</td>
<td align="center" colspan="1" rowspan="1" valign="top">DMs</td>
<td align="center" colspan="1" rowspan="1" valign="top">11.6</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B16">16</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">North Ireland</td>
<td align="center" colspan="1" rowspan="1" valign="top">DMs</td>
<td align="center" colspan="1" rowspan="1" valign="top">11.9</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B17">17</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">North Ireland</td>
<td align="center" colspan="1" rowspan="1" valign="top">DMs</td>
<td align="center" colspan="1" rowspan="1" valign="top">34</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B18">18</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">North UK</td>
<td align="center" colspan="1" rowspan="1" valign="top">DM1</td>
<td align="center" colspan="1" rowspan="1" valign="top">10.4</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B19">19</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Quebec</td>
<td align="center" colspan="1" rowspan="1" valign="top">DM1</td>
<td align="center" colspan="1" rowspan="1" valign="top">210</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B20">20</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Serbia, Belgrade</td>
<td align="center" colspan="1" rowspan="1" valign="top">DM1</td>
<td align="center" colspan="1" rowspan="1" valign="top">5.3</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B21">21</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Taiwan</td>
<td align="center" colspan="1" rowspan="1" valign="top">DM1</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.5</td>
<td align="center" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B22">22</xref>)</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="S2">
<title>Key Aspects in Myotonic Dystrophy Type 1</title>
<p>For DM1, there is a rough correlation between the expansion of CTG-repeats and the onset of symptoms as well as the severity of the disease; nevertheless predictions about the clinical features and the progression of the disease based on CTG-repeat size should be made very carefully (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>). 5 to 37 CTG-repeats are physiologic in healthy individuals. An expansion between 38 and 49 repeats does typically not cause any symptoms and reflects the premutation phenotype (<xref ref-type="bibr" rid="B3">3</xref>). The following four phenotypes are based on CTG-repeat sizes and onset of symtoms. It is important that phenotypes and CTG-repeat sizes do not show a linear and strict relationship and thus may overlap (<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B26">26</xref>):
<list list-type="bullet"><list-item><p>a mild phenotype with an expansion of 50–150 CTG-repeats,</p></list-item><list-item><p>a classic phenotype with a wide span from mild to severe symptoms and an expansion of 50–1,000 CTG-repeats,</p></list-item><list-item><p>a childhood/juvenile phenotype with early-onset and typically &gt;800 CTG-repeats, and</p></list-item><list-item><p>the most severe “congenital form” with usually &gt;1,000 CTG-repeats.</p></list-item></list></p>
<p>CTG-repeats will expand in every following generation, and fully penetrant alleles occur with &gt;50 CTG-repeats. This results in the so called anticipation, a clinical term describing an earlier onset with a more severe phenotype in the next generations (<xref ref-type="bibr" rid="B26">26</xref>). Furthermore, the repeat instability leads notably to premature aging of almost all organs, so DM1 may be counted among the progeroid diseases (<xref ref-type="bibr" rid="B27">27</xref>). The most typical appearance of DM1 is the “adult-onset” or “classic” phenotype with a CTG-repeat size ranging from 50 to &lt;1,000. It is characterized by a distinctive combination of muscular symptoms, such as facial weakness, ptosis, grip myotonia, and distal muscle weakness with muscular atrophy. The classic phenotype is typically accompanied by extramuscular symptoms like cognitive impairment, cataracts, and diabetes mellitus. Nevertheless, as this multisystem disorder often presents with a high variability, some patients may primarily show only non-specific extramuscular symptoms like fatigue, daytime sleepiness, gastrointestinal symptoms, or cardiac conduction defects in an early stage of the disease, which could delay the diagnosis. Mildly affected patients with CTG-repeat sizes 50–100 may have normal or only minimally shortened lifespan (<xref ref-type="bibr" rid="B28">28</xref>). Because of comorbidities, such as cardiac and pulmonary complications, life expectancy is, however, reduced in about 70% of the patients with the classic phenotype (<xref ref-type="bibr" rid="B25">25</xref>).</p>
</sec>
<sec id="S3">
<title>Special Aspects in Myotonic Dystrophy Type 2</title>
<p>DM2 (also referred to as proximal myotonic myopathy) is caused by the expansion of the tetranucleotide CCTG-repeat in the first intron of <italic>CNBP</italic> (cellular nucleic acid-binding protein), formerly known as zinc finger protein 9 (<italic>ZNF9</italic>) gene (<xref ref-type="bibr" rid="B29">29</xref>). Similar to DM1, these expansions are extremely unstable, causing widespread cellular abnormalities of mRNA splicing. In DM2, the expansion ranges from 75 to 11,000 with a mean of 5,000 CCTG-repeats. In contrast to DM1, there is no correlation between clinical phenotype and CCTG-repeat length and no anticipation has been observed (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B30">30</xref>).</p>
</sec>
<sec id="S4">
<title>Muscular Symptoms</title>
<sec id="S4-1">
<title>Muscular Weakness</title>
<p>The symptoms myotonia, muscular weakness, and muscular atrophy are the principal traits of DMs and gave the eponym for these two types of the disease. In DM1, patients present with characteristic distally predominant muscular atrophy and weakness mainly involving finger flexors, wrist flexors, and foot extensors (Figures <xref ref-type="fig" rid="F1">1</xref>A,B). The latter will cause foot drop and gait disturbance with repeated falls and injuries (<xref ref-type="bibr" rid="B31">31</xref>). In contrast to this, muscle weakness in DM2 is typically proximal and axial, affecting more consistently the neck flexors, hip flexors, and hip extensors (Figure <xref ref-type="fig" rid="F1">1</xref>C) (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B32">32</xref>). This predominantly proximal muscular involvement has been documented also by MRI studies that showed an early degeneration of the erector spinae and gluteus maximus muscles (<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B34">34</xref>). Muscle weakness is one of the most frequently reported symptoms in DM1 (&gt;45% of patients with adult phenotype) and DM2 (40–55% of patients) (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B32">32</xref>). Figure <xref ref-type="fig" rid="F1">1</xref>D illustrates the predominantly affected muscle groups of patients with DM1 and DM2 (see Table <xref ref-type="table" rid="T2">2</xref> for differentiating DM1 and DM2).</p>
<table-wrap id="T2" position="float">
<label>Table 2</label>
<caption>
<p>Core Clinical Symptoms helpful for differentiating DM1 and DM2.</p>
</caption>
<table frame="hsides" rules="rows">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top"></th>
<th align="left" colspan="1" rowspan="1" valign="top"></th>
<th align="left" colspan="1" rowspan="1" valign="top">DM1</th>
<th align="left" colspan="1" rowspan="1" valign="top">&gt;DM2</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Age of onset</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Depends on CTG-repeat-size, in common first symptoms earlier than in DM2</td>
<td align="left" colspan="1" rowspan="1" valign="top">30–40</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Family history</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Increasing severity of symptoms throughout generations (anticipation)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Variability in symptoms, but no evidence for anticipation</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">General appearance</td>
<td align="left" colspan="1" rowspan="1" valign="top">Head</td>
<td align="left" colspan="1" rowspan="1" valign="top">Forehead balding</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Face</td>
<td align="left" colspan="1" rowspan="1" valign="top">Myopathic face, temporal wasting, ptosis</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Bulbar</td>
<td align="left" colspan="1" rowspan="1" valign="top">Frequent: nasal/slurred speech, dysphagia</td>
<td align="left" colspan="1" rowspan="1" valign="top">In some cases: dysphagia</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Muscle</td>
<td align="left" colspan="1" rowspan="1" valign="top">Weakness</td>
<td align="left" colspan="1" rowspan="1" valign="top">Distal</td>
<td align="left" colspan="1" rowspan="1" valign="top">Proximal and axial</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Myotonia</td>
<td align="left" colspan="1" rowspan="1" valign="top">Handgrip, tongue</td>
<td align="left" colspan="1" rowspan="1" valign="top">mild proximal</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Atrophy</td>
<td align="left" colspan="1" rowspan="1" valign="top">Distal, early</td>
<td align="left" colspan="1" rowspan="1" valign="top">Proximal, late</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Myalgia</td>
<td align="left" colspan="1" rowspan="1" valign="top">Not typical, but may be secondary due to regional muscle imbalance</td>
<td align="left" colspan="1" rowspan="1" valign="top">Predominant</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Sleep disturbances</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Central sleep apnea, obstructive sleep apnea, respiratory muscle weakness</td>
<td align="left" colspan="1" rowspan="1" valign="top">Central sleep apnea</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Central nervous system</td>
<td align="left" colspan="1" rowspan="1" valign="top">Daytime sleepiness</td>
<td align="left" colspan="1" rowspan="1" valign="top">In almost every patient</td>
<td align="left" colspan="1" rowspan="1" valign="top">Frequent</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Concentration problems</td>
<td align="left" colspan="1" rowspan="1" valign="top">Frequent</td>
<td align="left" colspan="1" rowspan="1" valign="top">In some patients</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Hearing impaiment</td>
<td align="left" colspan="1" rowspan="1" valign="top">Rare in adults, more frequent in congenital DM</td>
<td align="left" colspan="1" rowspan="1" valign="top">Frequent</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Diagnostics</td>
<td align="left" colspan="1" rowspan="1" valign="top">Electromyography</td>
<td align="left" colspan="1" rowspan="1" valign="top">Myotonic discharges in clinically affected and not affected muscles</td>
<td align="left" colspan="1" rowspan="1" valign="top">Proximal, but can be absent</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p><bold>(A,B)</bold> Typical distal muscular atrophy in patients with DM1. <bold>(C)</bold> Atrophy of proximal muscles in a patient with DM2. <bold>(D)</bold> Figure illustrating the core phneotypes of DM1 (left) and DM2 (right). Regions of muscular involvement (weakness and atrophy) are highlighted in red.</p>
</caption>
<graphic xlink:href="fneur-09-00303-g001"></graphic>
</fig>
<p>The typical facial appearance of DM1 patients (“myopathic face”—“hatchet face”) is a prominent and early feature and is caused by weakness and atrophy of facial muscles and ptosis that might give the false impression of a tired, sad, or emotionless patient (<xref ref-type="bibr" rid="B35">35</xref>). Balding of the forehead and atrophying of the temporal muscle are often seen (Figure <xref ref-type="fig" rid="F2">2</xref>) and completes the overall picture of a patient with DM1. Severe weakness of orbiculari oculi muscles cause not only ptosis but also insufficient eyelid closure with risk of recurrent conjunctivitis. This facial muscle involvement is usually not seen in DM2 patients, thus it may help in differentiating DM1 from DM2 patients (Table <xref ref-type="table" rid="T2">2</xref>).</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>The characteristic face of a patient with DM1: long face, temporomandibular wasting, balding forehead.</p>
</caption>
<graphic xlink:href="fneur-09-00303-g002"></graphic>
</fig>
<p>Especially in patients with DM1, the speech can be nasal and slurred, due to the weakness of oropharyngeal muscles, sometimes causing chewing and swallowing difficulties.</p>
</sec>
<sec id="S4-2">
<title>Myotonia</title>
<p>Myotonia is a more frequent symptom in DM1 mainly affecting the fingers (grip myotonia), the jaw, and the tongue (<xref ref-type="bibr" rid="B36">36</xref>). Clinically, a warm-up phenomenon is usually observed when myotonia improves with repeated contractions, which is mostly true for grip myotonia, but also for myotonia of the tongue and the jaw (<xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B38">38</xref>). An increased excitability of muscle fibers is thought to be the cause for myotonia, leading to continuous discharges of repetitive action potentials after voluntary contraction or mechanical stimulation (<xref ref-type="bibr" rid="B39">39</xref>) in electromyography (EMG). These myotonic runs can be detected with EMG even in clinically unaffected muscles of DM1 patients, but can be rare or even be absent in DM2 (<xref ref-type="bibr" rid="B40">40</xref>). On a molecular basis, it has been suggested that myotonia is caused by mis-splicing of the chloride channel (<italic>CLCN1</italic>, ClC-1) due to misregulated MBNL1 and CUGBP1 (<xref ref-type="bibr" rid="B41">41</xref>). Recent studies have investigated the relationship between a central nervous system involvement and myotonia, suggesting that myotonia should no longer be considered as a solitary peripherally triggered muscular symptom (<xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B43">43</xref>). In one fMRI study, higher cerebral blood oxygen level-dependent signals (BOLD) in specific primary and secondary motor areas were found during myotonia episodes. This was interpreted as a relationship between myotonia and high-order motor control areas (<xref ref-type="bibr" rid="B44">44</xref>). In another study, the severity of myotonia correlated with diffuse white matter alterations in specific primary and secondary motor areas (<xref ref-type="bibr" rid="B45">45</xref>). There are contradictory reports about the correlation between myotonia, grip strength, and CTG-repeat length (<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B47">47</xref>) for DM1 patients. Overall, grip strength correlates negatively with CTG-repeat length in most studies, but this is not necessarily true for myotonia. In one recent study, there was a statistically significant correlation between grip myotonia and CTG-repeat length, but this was not clinically meaningful and not predictive (<xref ref-type="bibr" rid="B47">47</xref>).</p>
<p>Myotonia seems to be usually mild to moderate or even absent in many DM2 patients, impacting only minimally their quality of life (<xref ref-type="bibr" rid="B36">36</xref>). However, its occurrence in different cohorts ranges between 24 and 75% (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B40">40</xref>). This variability is partly due to the discrepancy sometimes observed between a history of myotonia reported by patients and the clinical evidence of myotonic phenomenon, which is observed on neurological examination only in a minority of DM2 patients. Few patients may, however, display a severe myotonia and in some of these cases additional mutations in ion channel genes CLCN1 and SCN4A have been identified (<xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B49">49</xref>). It is, therefore, advised to screen atypical cases with severe myotonia for mutation in these genes that act as phenotype modifier enhancing the myotonic phenomenon in DM2 (<xref ref-type="bibr" rid="B49">49</xref>). Particularly limb girdle myotonia is frequently neglected and underdiagnosed. With aging, the presence of myotonia gradually becomes less clinically relevant as it is overwhelmed by the gradually worsening of muscle weakness (<xref ref-type="bibr" rid="B32">32</xref>). This trend is also confirmed in studies assessing quality of life of DM2 patients, where significant predictors of worse QoL (quality of life) were older age, worse muscle strength, and higher level of fatigue (<xref ref-type="bibr" rid="B50">50</xref>).</p>
</sec>
<sec id="S4-3">
<title>Musculoskeletal Pain or Myalgia</title>
<p>Musculoskeletal pain or myalgia may be present in some DM1 patients, but is less frequent in comparison to DM2 (Table <xref ref-type="table" rid="T2">2</xref>). However, with the progression of the disease, a muscular imbalance due to weakness may occur and secondary complications such as regional myofascial pain or joint pain syndromes may develop even in DM1. In DM2, about 60% of patients complain of diffuse myalgia. These are usually exercise-related and worsen in cold temperatures (<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B51">51</xref>). Some patients consider pain as the most disabling symptom of the disease also because of its poor response to common analgesics (<xref ref-type="bibr" rid="B7">7</xref>). The pathophysiological mechanism of myalgia in DM2 is yet to be elucidated, but it is probably related to specific molecular changes occurring in the muscles of DM2 patients (<xref ref-type="bibr" rid="B52">52</xref>).</p>
<p>For adult-onset DM1, the first muscular symptoms can become apparent in early adulthood, but some patients may exhibit subtle symptoms like grip myotonia, ptosis or slurred speech in childhood. Patients with classic DM1 are typically diagnosed at around 30 years, but mildly affected patients with CTG-length 50–100 may present solely some slight myotonia or cataracts and may have their diagnosis delayed until they are around 40 years old (<xref ref-type="bibr" rid="B28">28</xref>). The clinical onset of DM2 typically occurs later than DM1, around the third to fourth decade; it may, however, often go unrecognized for several years due to only mild or unspecific clinical symptoms like myalgia or muscle cramps.</p>
</sec>
<sec id="S4-4">
<title>Muscular Respiratory Symptoms</title>
<p>Respiratory muscle weakness will occur in a high percentage of the patients with DM1 in an early stage of the disease and chronic respiratory failure may develop (<xref ref-type="bibr" rid="B53">53</xref>). Expiratory muscles seem to be affected sooner than inspiratory muscles, resulting in early recurrent pneumonia due to a weak cough and insufficient airway clearance. The exact prevalence of respiratory insufficiency in DM1 is unclear because symptoms of nocturnal hypoventilation overlap with typical neuropsychological symptoms like fatigue, daytime sleepiness, and concentration difficulties (<xref ref-type="bibr" rid="B54">54</xref>). As both respiratory muscle weakness and cardiac symptoms account most for the reduced survival of the patients, repeated testing for early diagnosis is essential. A pure respiratory muscle weakness rarely occurs in DM2 and only about 6–15% of patients require non-invasive ventilation (<xref ref-type="bibr" rid="B55">55</xref>).</p>
</sec>
</sec>
<sec id="S5">
<title>Extramuscular Symptoms</title>
<sec id="S5-1">
<title>CNS Symptoms</title>
<p>Fatigue, daytime sleepiness, and concentration difficulties are frequently reported symptoms in DMs. In DM1, cognitive deficits were initially attributed to a low IQ or mental retardation, but recent studies show that this assumption was wrong for a large cohort of patients and mainly applies for cases of congenital myotonic dystrophy (CDM). In fact, for the classic phenotype of DM1, neuropsychological deficits are as variable as muscular symptoms, and even recent publications about the correlation of CTG-repeat size and neuropsychological deficits show contradictory study results (<xref ref-type="bibr" rid="B56">56</xref>–<xref ref-type="bibr" rid="B58">58</xref>). There seems to be a correlation between diffuse brain alterations in primarily white and secondary gray matter, linking the DM1 to the group of brain disconnection disorders (<xref ref-type="bibr" rid="B59">59</xref>). Caso et al. investigated 51 DM1 patients and found a correlation between changes in brain white matter and cognitive impairment (<xref ref-type="bibr" rid="B60">60</xref>). Cerebral white matter hyperintensities have been observed in both DM1 and DM2 patients, especially in those older than 40 years, but their clinical and functional significance still remains unclear (<xref ref-type="bibr" rid="B61">61</xref>–<xref ref-type="bibr" rid="B63">63</xref>). In a recent study about the educational profile of a large cohort of young DM1 patients, no significant differences compared to the healthy population were found (<xref ref-type="bibr" rid="B35">35</xref>), assuming that cognitive and concentration disturbances may occur later in the course of the disease in the context of a variable premature cognitive decline, as suggested by the study of Modoni et al. (<xref ref-type="bibr" rid="B56">56</xref>). Mild cognitive and behavioral symptoms are also present in DM2 patients. In particular, altered visuo-spatial and executive functions, reduced attention and flexibility of thinking, avoidant behavioral trait, and depression have been detected in these patients (<xref ref-type="bibr" rid="B63">63</xref>, <xref ref-type="bibr" rid="B64">64</xref>). In many cases, neuropsychological disturbances jeopardize the ability to work and reduce the quality of life more than muscular symptoms.</p>
<p>Excessive daytime sleepiness, fatigue, and concentration difficulties may also be caused by central sleep disturbances or sleep apnea. Sleep-disordered breathing is one of the earliest manifestations and occurs in a high percentage of patients with DM1 (<xref ref-type="bibr" rid="B65">65</xref>), but overlapping symptoms of nocturnal hypoventilation and CNS symptoms may delay diagnosis and treatment. Chronic central sleep-disordered breathing has an impact on quality of life, morbidity, and mortality and should be assessed frequently in every patient with DM1 (<xref ref-type="bibr" rid="B54">54</xref>, <xref ref-type="bibr" rid="B55">55</xref>, <xref ref-type="bibr" rid="B66">66</xref>).</p>
<p>Until now, little is known about changes in CNS causing cognitive deficits and central sleep disrupted breathing. Almost every clinical study is conducted with the usually more affected DM1 patients, therefore data for DM2 patients are limited. On a molecular basis, MBNL1 and probably CELF may both be involved in CNS alterations, but little is known about molecular defects causing highly variable CNS symptoms in DM1 (<xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B43">43</xref>). The above mentioned aspects lead to a discussion as to whether CNS dysfunction is caused by altered neurodevelopment, by neuro-dysfunction or by neurodegeneration within the definition of progeroid diseases (<xref ref-type="bibr" rid="B67">67</xref>). The hypothesis of a neurodegenerative disease is endorsed by findings of tau pathology and neurofibrillary degenerations, even if no correlations with CTG-repeat length were found (<xref ref-type="bibr" rid="B68">68</xref>). Overall, CNS dysfunction seems to be multifactorial.</p>
</sec>
<sec id="S5-2">
<title>Eyes</title>
<p>The most frequent, early and typical extramuscular manifestation is the occurrence of early-onset cataract, observed in about 50–60% of patients (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B69">69</xref>). A medical history of cataract surgery in combination with muscular symptoms often leads to the diagnosis of DM, even in mildly affected patients without any sign of muscular impairment (<xref ref-type="bibr" rid="B70">70</xref>–<xref ref-type="bibr" rid="B72">72</xref>). The mechanisms underlying the pathophysiology of cataract in DMs are still largely unknown. At first, a potential effect of the CTG-mutation on the expression of neighboring genes such as SIX5 was considered in DM1 (<xref ref-type="bibr" rid="B73">73</xref>). But recent findings showed that SIX5 knock-out mice develop the nuclear type of cataract and not the posterior subcapsular/cortical type that are commonly observed in DMs. In addition, SIX5 is not adjacent to the DM2 repeat expansion so that this mechanism could not explain cataracts in DM2. More recent studies of global transcription performed on samples of lens epithelium in patients affected by DM1, DM2, and controls, identified a high similarity as regards the pattern of gene expression between DM1 and DM2 and hypothesized that common molecular mechanisms should be involved in cataract formation probably involving interferon signaling pathways (<xref ref-type="bibr" rid="B74">74</xref>, <xref ref-type="bibr" rid="B75">75</xref>).</p>
</sec>
<sec id="S5-3">
<title>Endocrine Symptoms</title>
<p>Endocrine dysfunctions such as diabetes, hypogonadism, and secondary hyperparathyroidism with decreased Vitamin-D levels are frequent in DMs and their occurrence increases with progression of the disease (<xref ref-type="bibr" rid="B76">76</xref>–<xref ref-type="bibr" rid="B78">78</xref>). A cross-sectional study on 68 DM1 patients showed at least one endocrine dysfunction in 44% at baseline and in 84% after 8 years (<xref ref-type="bibr" rid="B76">76</xref>). Diabetes mellitus, if not properly treated, may complicate and aggravate the clinical picture due to diabetic polyneuropathy with worsening of gait instability and distal weakness. Hyperparathyroidism may contribute to fatigue and muscle impairment (<xref ref-type="bibr" rid="B76">76</xref>). More rarely, abnormalities in growth hormone secretion and glucose intolerance may be observed (<xref ref-type="bibr" rid="B79">79</xref>).</p>
</sec>
<sec id="S5-4">
<title>Hearing Impairment</title>
<p>Some degree of hearing loss has been described in DM2 since its first description (<xref ref-type="bibr" rid="B80">80</xref>). A recent systematic study on 56 Dutch and French DM2 patients then demonstrated that a mild to moderate hearing impairment was present in about 60% of examined patients. It is mostly a cochlear sensorineural hearing impairment which may be interpreted as an early presbycusis (<xref ref-type="bibr" rid="B81">81</xref>), well fitting in the interpretation of DMs as premature aging diseases. Similar features of cochlear impairment have also been described in some studies on DM1 patients (<xref ref-type="bibr" rid="B82">82</xref>).</p>
</sec>
<sec id="S5-5">
<title>Cardiac Symptoms</title>
<p>In DMs, cardiac involvement is common. Cardiologic comorbidities include arrhythmias, atrial fibrillation, and conduction defects (e.g., AV-blocks) and often requires the implantation of pacemakers. Other infrequent manifestations are sudden death, heart failure, Brugada syndrome, ischemic heart disease, and mitral valve prolapse (<xref ref-type="bibr" rid="B83">83</xref>, <xref ref-type="bibr" rid="B84">84</xref>). Dilated cardiomyopathies may also occur in some patients, but are not frequently found. Cardiac abnormalities in DM2 are similar to those observed in DM1 but occur less frequently. According to a recent observational case–control study on a large cohort of DM2/DM1 patients, it emerged that electrocardiographic abnormalities as PR &gt; 200 ms and QRS &gt; 100 ms were more frequent in DM1 (respectively, 31 and 48%) than DM2 patients (10 and 17%). Of those, 6 DM2 vs. 28 DM1 patients needed a pacemaker/implanted cardioverter (<xref ref-type="bibr" rid="B85">85</xref>). In the same study, echocardiography did not show any significant structural abnormalities but it was previously reported that a cardiomyopathy might occur in about 3% of DM2 patients. In DM1, the severity of cardiac involvement seems directly related with the size of CTG-expansion as recently studied by Chong-Nguyen et al. (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B85">85</xref>, <xref ref-type="bibr" rid="B86">86</xref>). Atrial fibrillations and arrhythmias increase the risk of cerebral ischemia (<xref ref-type="bibr" rid="B87">87</xref>) and mortality and morbidity significantly depend on early cardiologic diagnosis and treatment (<xref ref-type="bibr" rid="B83">83</xref>).</p>
</sec>
<sec id="S5-6">
<title>Gastrointestinal Symptoms</title>
<p>Along with elevations of creatine kinase, elevations of AST and ALT are frequent in patients with DM (<xref ref-type="bibr" rid="B88">88</xref>). In some cases, liver biopsies are performed because of these elevated “hepatic” enzymes without retrieving any pathologic result. The elevation of gamma-GT is suggested to be caused by contractions of bile canaliculi and bile ductules, whereas elevated levels of AST and ALT have their origin in skeletal muscle and go along with elevations of creatine kinase (<xref ref-type="bibr" rid="B89">89</xref>).</p>
<p>Alternating constipation, pseudo-constipation, bloating, and diarrhea are frequently reported symptoms in DM1, accompanied by stomach cramps, reflux, and regurgitation. They are caused by involvement of smooth and striated muscles and endocrine dysfunctions (<xref ref-type="bibr" rid="B90">90</xref>, <xref ref-type="bibr" rid="B91">91</xref>). Swallowing problems are typical for DM1 patients and due to reduced oral transport that is caused by myotonia and weakness of the tongue. Dysphagia is caused by reduced swallowing reflex and reduced esophageal motility (<xref ref-type="bibr" rid="B92">92</xref>) which causes the major clinical problem by risk of aspiration. In conjunction with weakness of early affected expiratory muscles, this results in recurrent pneumonia and increased risk of death. A reduced or absent gastrointestinal peristaltic movement was earlier shown in radiological studies as well as delayed intestinal transits (<xref ref-type="bibr" rid="B93">93</xref>). Megacolon with the risk of ileus, volvulus and rupture, is a significant and life-threatening complication. Delayed emptying of the gall bladder may increase the risk for gallstones.</p>
</sec>
<sec id="S5-7">
<title>Cancer</title>
<p>A higher incidence for neoplasms was found in several studies (<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B94">94</xref>, <xref ref-type="bibr" rid="B95">95</xref>), most of them showed a predisposition in patients with DM1 for cancers such as skin cancer (like benign calcifying cutaneous tumors, pilomatricomas), thyroid, testicular, and prostate cancer. Because of the limited number of high-quality surveys and studies about the prevalence of cancer in DM1, further research is needed. A survey from the UK DM registry showed that 12.4% of the DM1/DM2 patients reported at least one benign tumor and 6.2% reported at least one malignant tumor with a high incidence of skin tumors (<xref ref-type="bibr" rid="B96">96</xref>), but there was no epidemiologic correlation with a non-DM-population.</p>
</sec>
<sec id="S5-8">
<title>Peripheral Polyneuropathy</title>
<p>There is some debate as to whether peripheral neuropathy is a multisystemic manifestation of DMs or are caused by metabolic and endocrine dysfunctions. Its manifestation is not typical at early stages of the disease but may occur in about one-third of patients in later stages (<xref ref-type="bibr" rid="B97">97</xref>) of DM1 patients and contributes to balance impairment and increased risk of falls (<xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B98">98</xref>). There were no significant correlations between age, duration of neuromuscular symptoms or CTG-repeat size (<xref ref-type="bibr" rid="B98">98</xref>, <xref ref-type="bibr" rid="B99">99</xref>), suggesting that the affection of peripheral nerve system is secondary to metabolic and endocrine dysfunctions.</p>
</sec>
</sec>
<sec id="S6">
<title>Congenital Myotonic Dystrophy (CDM)</title>
<p>Patients with congenital DM1 have large CTG-expansions of more than 800, usually around 1,000. Characteristically, these large expansions are caused by maternal transmission, but CDM with paternal transmission is also known (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B100">100</xref>–<xref ref-type="bibr" rid="B102">102</xref>). Clinically, CDM patients are severely affected and symptoms are often present before birth as polyhydramnios and reduced fetal movement. Hypotonia, generalized weakness, hyporeflexia, bilateral talipes, contractures, arthrogryposis, facial dysmorphia (carp mouth, ptosis, long neck and face, temporal muscle atrophy), and a weak cry are typical symptoms at birth or in the first days after delivery. Weak sucking and respiratory insufficiency often make ventilatory support unavoidable. Respiratory insufficiency is present in about 50% of newborns and is the main cause of dramatically reduced survival with a mortality rate of 30–40% (<xref ref-type="bibr" rid="B103">103</xref>). Infants who survive will typically reach their motor and cognitive milestones with some delay but might be able to walk independently. Similarly to DM1, a distal weakness is typical in CDM and a proximal involvement indicates a poor prognosis (<xref ref-type="bibr" rid="B104">104</xref>). Besides muscular symptoms, cognitive impairment, and neuropsychological disorders are the most common and variable manifestations in CDM. Symptoms range from intellectual impairment to selective cognitive impairment, apathy, and autism, as well as impaired attention, severe anxiety, and mood and depression syndromes (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B102">102</xref>, <xref ref-type="bibr" rid="B105">105</xref>–<xref ref-type="bibr" rid="B107">107</xref>). In the course of the disease, patients might require special schooling. In their third and fourth decades, patients may develop secondary complications, such as severe contractures, scoliosis, and worsening of cardiorespiratory symptoms (<xref ref-type="bibr" rid="B4">4</xref>).</p>
</sec>
<sec id="S7">
<title>Childhood/Juvenile Onset DM1</title>
<p>The childhood and juvenile onset DM1 echoes the broad overlapping spectrum of symptoms of the congenital and the adult phenotypes. Commonly, there is an expansion of CTG-repeats of more than 800 repeats. First clinical symptoms may become apparent at age 1–10 for childhood onset and at age 10–20 for juvenile onset (<xref ref-type="bibr" rid="B3">3</xref>). Neurocognitive symptoms such as learning disability and learning difficulties are often prominent at age around 10 years and may become earlier apparent than muscular symptoms (<xref ref-type="bibr" rid="B107">107</xref>). In contrast to CDM, prenatal abnormalities or muscular symptoms right after delivery (neonatal hypotonia, sucking and swallowing difficulties and secondary dysmorphic features) are not typical, but a mild facial weakness or subtle facial dysmorphia may occur (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B108">108</xref>). Early motor development is normal or only slightly delayed. Principal complaints in early childhood are speech and learning difficulties because of a mental handicap. At school, learning difficulties may become apparent and sometimes require special education. A study on 28 childhood-DM-patients showed that the full-scale IQ was significantly decreased (73.6) and 68% of the patients had repeated at least one school grade. 54% had additional psychiatric symptoms such as anxiety disorder, mood disorder, and attention-deficit-hyperactivity disorder (<xref ref-type="bibr" rid="B107">107</xref>). In adolescence, patients may show typical muscular and non-muscular symptoms of adult-onset DM1, e.g., like distal weakness, clinical myotonia, or gastrointestinal symptoms. Cardiologic symptoms, such as cardiac arrhythmias or cardiomyopathy, may occur, also leading to severe complications and sudden death (<xref ref-type="bibr" rid="B83">83</xref>). Life expectancy is not necessarily reduced, as long as core symptoms are recognized and treated sufficiently.</p>
</sec>
<sec id="S8">
<title>Conclusion</title>
<p>Myotonic dystrophies represent the most variable clinical phenotypes, so treatment stratification is key for any modern therapeutic approach. We still need much more understanding of the signs and symptoms of DM patients in correlation to their molecular origins.</p>
</sec>
<sec id="S9">
<title>Author Contributions</title>
<p>SW: review of publications, writing, critical revision of manuscript for intellectual content, and final approval of the manuscript. FM: review of publications, writing, and critical revision of manuscript for intellectual content. BS: critical revision of manuscript for intellectual content.</p>
</sec>
<sec id="S10">
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suominen</surname><given-names>T</given-names></name><name><surname>Bachinski</surname><given-names>LL</given-names></name><name><surname>Auvinen</surname><given-names>S</given-names></name><name><surname>Hackman</surname><given-names>P</given-names></name><name><surname>Baggerly</surname><given-names>KA</given-names></name><name><surname>Angelini</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title>Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland</article-title>. <source/>Eur J Hum Genet (<year>2011</year>) <volume>19</volume>(<issue>7</issue>):<fpage>776</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="doi">10.1038/ejhg.2011.23</pub-id><pub-id pub-id-type="pmid">21364698</pub-id></mixed-citation>
</ref>
<ref id="B2">
<label>2</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Udd</surname><given-names>B</given-names></name><name><surname>Meola</surname><given-names>G</given-names></name><name><surname>Krahe</surname><given-names>R</given-names></name><name><surname>Wansink</surname><given-names>DG</given-names></name><name><surname>Bassez</surname><given-names>G</given-names></name><name><surname>Kress</surname><given-names>W</given-names></name><etal></etal></person-group>
<article-title>Myotonic dystrophy type 2 (DM2) and related disorders report of the 180th ENMC workshop including guidelines on diagnostics and management 3-5 December 2010, Naarden, The Netherlands</article-title>. <source/>Neuromuscul Disord (<year>2011</year>) <volume>21</volume>(<issue>6</issue>):<fpage>443</fpage>–<lpage>50</lpage>.<pub-id pub-id-type="doi">10.1016/j.nmd.2011.03.013</pub-id><pub-id pub-id-type="pmid">21543227</pub-id></mixed-citation>
</ref>
<ref id="B3">
<label>3</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>G</given-names></name><name><surname>Cardamone</surname><given-names>M</given-names></name><name><surname>Farrar</surname><given-names>M</given-names></name></person-group>. <article-title>Congenital and childhood myotonic dystrophy: current aspects of disease and future directions</article-title>. <source/>World J Clin Pediatr (<year>2015</year>) <volume>4</volume>(<issue>4</issue>):<fpage>66</fpage>–<lpage>80</lpage>.<pub-id pub-id-type="doi">10.5409/wjcp.v4.i4.66</pub-id><pub-id pub-id-type="pmid">26566479</pub-id></mixed-citation>
</ref>
<ref id="B4">
<label>4</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meola</surname><given-names>G</given-names></name><name><surname>Cardani</surname><given-names>R</given-names></name></person-group>. <article-title>Myotonic dystrophies: an update on clinical aspects, genetic, pathology, and molecular pathomechanisms</article-title>. <source/>Biochim Biophys Acta (<year>2015</year>) <volume>1852</volume>(<issue>4</issue>):<fpage>594</fpage>–<lpage>606</lpage>.<pub-id pub-id-type="doi">10.1016/j.bbadis.2014.05.019</pub-id><pub-id pub-id-type="pmid">24882752</pub-id></mixed-citation>
</ref>
<ref id="B5">
<label>5</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medica</surname><given-names>I</given-names></name><name><surname>Markovic</surname><given-names>D</given-names></name><name><surname>Peterlin</surname><given-names>B</given-names></name></person-group>. <article-title>Genetic epidemiology of myotonic dystrophy in Istria, Croatia</article-title>. <source/>Acta Neurol Scand (<year>1997</year>) <volume>95</volume>(<issue>3</issue>):<fpage>164</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1111/j.1600-0404.1997.tb00089.x</pub-id><pub-id pub-id-type="pmid">9088385</pub-id></mixed-citation>
</ref>
<ref id="B6">
<label>6</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vohanka</surname><given-names>S</given-names></name><name><surname>Parmova</surname><given-names>O</given-names></name><name><surname>Mazanec</surname><given-names>R</given-names></name><name><surname>Strenkova</surname><given-names>J</given-names></name><name><surname>Ridzon</surname><given-names>P</given-names></name><name><surname>Ehler</surname><given-names>E</given-names></name><etal></etal></person-group>
<article-title>Myotonic dystrophy in Czech Republic: data from the national registry</article-title>. <source/>J Neurol Sci (<year>2015</year>) <volume>357</volume>:<fpage>e347</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.jns.2015.08.1232</pub-id></mixed-citation>
</ref>
<ref id="B7">
<label>7</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Udd</surname><given-names>B</given-names></name><name><surname>Meola</surname><given-names>G</given-names></name><name><surname>Krahe</surname><given-names>R</given-names></name><name><surname>Thornton</surname><given-names>C</given-names></name><name><surname>Ranum</surname><given-names>LP</given-names></name><name><surname>Bassez</surname><given-names>G</given-names></name><etal></etal></person-group>
<article-title>140th ENMC International Workshop: myotonic dystrophy DM2/PROMM and other myotonic dystrophies with guidelines on management</article-title>. <source/>Neuromuscul Disord (<year>2006</year>) <volume>16</volume>(<issue>6</issue>):<fpage>403</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="doi">10.1016/j.nmd.2006.03.010</pub-id><pub-id pub-id-type="pmid">16684600</pub-id></mixed-citation>
</ref>
<ref id="B8">
<label>8</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suominen</surname><given-names>S</given-names></name><name><surname>Koskenvuo</surname><given-names>K</given-names></name><name><surname>Sillanmaki</surname><given-names>L</given-names></name><name><surname>Vahtera</surname><given-names>J</given-names></name><name><surname>Korkeila</surname><given-names>K</given-names></name><name><surname>Kivimaki</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Non-response in a nationwide follow-up postal survey in Finland: a register-based mortality analysis of respondents and non-respondents of the Health and Social Support (HeSSup) Study</article-title>. <source/>BMJ Open (<year>2012</year>) <volume>2</volume>(<issue>2</issue>):<fpage>e000657</fpage>.<pub-id pub-id-type="doi">10.1136/bmjopen-2011-000657</pub-id><pub-id pub-id-type="pmid">22422917</pub-id></mixed-citation>
</ref>
<ref id="B9">
<label>9</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoser</surname><given-names>BG</given-names></name><name><surname>Ricker</surname><given-names>K</given-names></name><name><surname>Schneider-Gold</surname><given-names>C</given-names></name><name><surname>Hengstenberg</surname><given-names>C</given-names></name><name><surname>Durre</surname><given-names>J</given-names></name><name><surname>Bultmann</surname><given-names>B</given-names></name><etal></etal></person-group>
<article-title>Sudden cardiac death in myotonic dystrophy type 2</article-title>. <source/>Neurology (<year>2004</year>) <volume>63</volume>(<issue>12</issue>):<fpage>2402</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1212/01.WNL.0000147335.10783.E4</pub-id><pub-id pub-id-type="pmid">15623712</pub-id></mixed-citation>
</ref>
<ref id="B10">
<label>10</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segel</surname><given-names>R</given-names></name><name><surname>Silverstein</surname><given-names>S</given-names></name><name><surname>Lerer</surname><given-names>I</given-names></name><name><surname>Kahana</surname><given-names>E</given-names></name><name><surname>Meir</surname><given-names>R</given-names></name><name><surname>Sagi</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Prevalence of myotonic dystrophy in Israeli Jewish communities: inter-community variation and founder premutations</article-title>. <source/>Am J Med Genet A (<year>2003</year>) <volume>119A</volume>(<issue>3</issue>):<fpage>273</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1002/ajmg.a.20177</pub-id><pub-id pub-id-type="pmid">12784291</pub-id></mixed-citation>
</ref>
<ref id="B11">
<label>11</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinessi</surname><given-names>L</given-names></name><name><surname>Bergamini</surname><given-names>L</given-names></name><name><surname>Cantello</surname><given-names>R</given-names></name><name><surname>Di Tizio</surname><given-names>C</given-names></name></person-group>. <article-title>Myotonia congenita and myotonic dystrophy: descriptive epidemiological investigation in Turin, Italy (1955-1979)</article-title>. <source/>Ital J Neurol Sci (<year>1982</year>) <volume>3</volume>(<issue>3</issue>):<fpage>207</fpage>–<lpage>10</lpage>.<pub-id pub-id-type="doi">10.1007/BF02043311</pub-id><pub-id pub-id-type="pmid">7161034</pub-id></mixed-citation>
</ref>
<ref id="B12">
<label>12</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siciliano</surname><given-names>G</given-names></name><name><surname>Manca</surname><given-names>M</given-names></name><name><surname>Gennarelli</surname><given-names>M</given-names></name><name><surname>Angelini</surname><given-names>C</given-names></name><name><surname>Rocchi</surname><given-names>A</given-names></name><name><surname>Iudice</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Epidemiology of myotonic dystrophy in Italy: re-apprisal after genetic diagnosis</article-title>. <source/>Clin Genet (<year>2001</year>) <volume>59</volume>(<issue>5</issue>):<fpage>344</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1034/j.1399-0004.2001.590508.x</pub-id><pub-id pub-id-type="pmid">11359466</pub-id></mixed-citation>
</ref>
<ref id="B13">
<label>13</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanacore</surname><given-names>N</given-names></name><name><surname>Rastelli</surname><given-names>E</given-names></name><name><surname>Antonini</surname><given-names>G</given-names></name><name><surname>Bianchi</surname><given-names>ML</given-names></name><name><surname>Botta</surname><given-names>A</given-names></name><name><surname>Bucci</surname><given-names>E</given-names></name><etal></etal></person-group>
<article-title>An age-standardized prevalence estimate and a sex and age distribution of myotonic dystrophy types 1 and 2 in the Rome province, Italy</article-title>. <source/>Neuroepidemiology (<year>2016</year>) <volume>46</volume>(<issue>3</issue>):<fpage>191</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1159/000444018</pub-id><pub-id pub-id-type="pmid">26882032</pub-id></mixed-citation>
</ref>
<ref id="B14">
<label>14</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakagawa</surname><given-names>M</given-names></name><name><surname>Nakahara</surname><given-names>K</given-names></name><name><surname>Yoshidome</surname><given-names>H</given-names></name><name><surname>Suehara</surname><given-names>M</given-names></name><name><surname>Higuchi</surname><given-names>I</given-names></name><name><surname>Fujiyama</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Epidemiology of progressive muscular dystrophy in Okinawa, Japan. Classification with molecular biological techniques</article-title>. <source/>Neuroepidemiology (<year>1991</year>) <volume>10</volume>(<issue>4</issue>):<fpage>185</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1159/000110268</pub-id><pub-id pub-id-type="pmid">1745328</pub-id></mixed-citation>
</ref>
<ref id="B15">
<label>15</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burcet</surname><given-names>J</given-names></name><name><surname>Canellas</surname><given-names>F</given-names></name><name><surname>Cavaller</surname><given-names>G</given-names></name><name><surname>Vich</surname><given-names>M</given-names></name></person-group>. <article-title>[Epidemiologic study of myotonic dystrophy on the island of Mallorca]</article-title>. <source/>Neurologia (<year>1992</year>) <volume>7</volume>(<issue>2</issue>):<fpage>61</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">1369611</pub-id></mixed-citation>
</ref>
<ref id="B16">
<label>16</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>C</given-names></name><name><surname>Kidd</surname><given-names>A</given-names></name><name><surname>Hammond-Tooke</surname><given-names>G</given-names></name></person-group>. <article-title>Myotonic dystrophy in Otago, New Zealand</article-title>. <source/>N Z Med J (<year>2006</year>) <volume>119</volume>(<issue>1241</issue>):<fpage>U2145</fpage>.<pub-id pub-id-type="pmid">16964297</pub-id></mixed-citation>
</ref>
<ref id="B17">
<label>17</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magee</surname><given-names>A</given-names></name><name><surname>Nevin</surname><given-names>NC</given-names></name></person-group>. <article-title>The epidemiology of myotonic dystrophy in Northern Ireland</article-title>. <source/>Community Genet (<year>1999</year>) <volume>2</volume>(<issue>4</issue>):<fpage>179</fpage>–<lpage>83</lpage>.<pub-id pub-id-type="doi">10.1159/000016209</pub-id><pub-id pub-id-type="pmid">14960839</pub-id></mixed-citation>
</ref>
<ref id="B18">
<label>18</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>MI</given-names></name><name><surname>Hicks</surname><given-names>EM</given-names></name><name><surname>Nevin</surname><given-names>NC</given-names></name><name><surname>Patterson</surname><given-names>VH</given-names></name></person-group>
<article-title>The prevalence of inherited neuromuscular disease in Northern Ireland</article-title>. <source/>Neuromuscul Disord (<year>1996</year>) <volume>6</volume>(<issue>1</issue>):<fpage>69</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="doi">10.1016/0960-8966(94)00017-4</pub-id><pub-id pub-id-type="pmid">8845721</pub-id></mixed-citation>
</ref>
<ref id="B19">
<label>19</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norwood</surname><given-names>FL</given-names></name><name><surname>Harling</surname><given-names>C</given-names></name><name><surname>Chinnery</surname><given-names>PF</given-names></name><name><surname>Eagle</surname><given-names>M</given-names></name><name><surname>Bushby</surname><given-names>K</given-names></name><name><surname>Straub</surname><given-names>V</given-names></name></person-group>. <article-title>Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population</article-title>. <source/>Brain (<year>2009</year>) <volume>132</volume>(<issue>Pt 11</issue>):<fpage>3175</fpage>–<lpage>86</lpage>.<pub-id pub-id-type="doi">10.1093/brain/awp236</pub-id><pub-id pub-id-type="pmid">19767415</pub-id></mixed-citation>
</ref>
<ref id="B20">
<label>20</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouchard</surname><given-names>G</given-names></name><name><surname>Roy</surname><given-names>R</given-names></name><name><surname>Declos</surname><given-names>M</given-names></name><name><surname>Mathieu</surname><given-names>J</given-names></name><name><surname>Kouladjian</surname><given-names>K</given-names></name></person-group>. <article-title>Origin and diffusion of the myotonic dystrophy gene in the Saguenay region (Quebec)</article-title>. <source/>Can J Neurol Sci (<year>1989</year>) <volume>16</volume>(<issue>1</issue>):<fpage>119</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1017/S0317167100028651</pub-id><pub-id pub-id-type="pmid">2924205</pub-id></mixed-citation>
</ref>
<ref id="B21">
<label>21</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mladenovic</surname><given-names>J</given-names></name><name><surname>Pekmezovic</surname><given-names>T</given-names></name><name><surname>Todorovic</surname><given-names>S</given-names></name><name><surname>Rakocevic-Stojanovic</surname><given-names>V</given-names></name><name><surname>Savic</surname><given-names>D</given-names></name><name><surname>Romac</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Epidemiology of myotonic dystrophy type 1 (Steinert disease) in Belgrade (Serbia)</article-title>. <source/>Clin Neurol Neurosurg (<year>2006</year>) <volume>108</volume>(<issue>8</issue>):<fpage>757</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="doi">10.1016/j.clineuro.2006.04.004</pub-id><pub-id pub-id-type="pmid">16713671</pub-id></mixed-citation>
</ref>
<ref id="B22">
<label>22</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsiao</surname><given-names>KM</given-names></name><name><surname>Chen</surname><given-names>SS</given-names></name><name><surname>Li</surname><given-names>SY</given-names></name><name><surname>Chiang</surname><given-names>SY</given-names></name><name><surname>Lin</surname><given-names>HM</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Epidemiological and genetic studies of myotonic dystrophy type 1 in Taiwan</article-title>. <source/>Neuroepidemiology (<year>2003</year>) <volume>22</volume>(<issue>5</issue>):<fpage>283</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1159/000071191</pub-id><pub-id pub-id-type="pmid">12902623</pub-id></mixed-citation>
</ref>
<ref id="B23">
<label>23</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunner</surname><given-names>HG</given-names></name><name><surname>Bruggenwirth</surname><given-names>HT</given-names></name><name><surname>Nillesen</surname><given-names>W</given-names></name><name><surname>Jansen</surname><given-names>G</given-names></name><name><surname>Hamel</surname><given-names>BC</given-names></name><name><surname>Hoppe</surname><given-names>RL</given-names></name><etal></etal></person-group>
<article-title>Influence of sex of the transmitting parent as well as of parental allele size on the CTG expansion in myotonic dystrophy (DM)</article-title>. <source/>Am J Hum Genet (<year>1993</year>) <volume>53</volume>(<issue>5</issue>):<fpage>1016</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="pmid">8213829</pub-id></mixed-citation>
</ref>
<ref id="B24">
<label>24</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouchard</surname><given-names>JP</given-names></name><name><surname>Cossette</surname><given-names>L</given-names></name><name><surname>Bassez</surname><given-names>G</given-names></name><name><surname>Puymirat</surname><given-names>J</given-names></name></person-group>. <article-title>Natural history of skeletal muscle involvement in myotonic dystrophy type 1: a retrospective study in 204 cases</article-title>. <source/>J Neurol (<year>2015</year>) <volume>262</volume>(<issue>2</issue>):<fpage>285</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="doi">10.1007/s00415-014-7570-x</pub-id><pub-id pub-id-type="pmid">25380585</pub-id></mixed-citation>
</ref>
<ref id="B25">
<label>25</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>C</given-names></name><name><surname>Hilton-Jones</surname><given-names>D</given-names></name></person-group>. <article-title>Myotonic dystrophy: diagnosis, management and new therapies</article-title>. <source/>Curr Opin Neurol (<year>2014</year>) <volume>27</volume>(<issue>5</issue>):<fpage>599</fpage>–<lpage>606</lpage>.<pub-id pub-id-type="doi">10.1097/WCO.0000000000000128</pub-id><pub-id pub-id-type="pmid">25121518</pub-id></mixed-citation>
</ref>
<ref id="B26">
<label>26</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Antonio</surname><given-names>M</given-names></name><name><surname>Dogan</surname><given-names>C</given-names></name><name><surname>Hamroun</surname><given-names>D</given-names></name><name><surname>Mati</surname><given-names>M</given-names></name><name><surname>Zerrouki</surname><given-names>S</given-names></name><name><surname>Eymard</surname><given-names>B</given-names></name><etal></etal></person-group>
<article-title>Unravelling the myotonic dystrophy type 1 clinical spectrum: a systematic registry-based study with implications for disease classification</article-title>. <source/>Rev Neurol (<year>2016</year>) <volume>172</volume>(<issue>10</issue>):<fpage>572</fpage>–<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1016/j.neurol.2016.08.003</pub-id><pub-id pub-id-type="pmid">27665240</pub-id></mixed-citation>
</ref>
<ref id="B27">
<label>27</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mateos-Aierdi</surname><given-names>AJ</given-names></name><name><surname>Goicoechea</surname><given-names>M</given-names></name><name><surname>Aiastui</surname><given-names>A</given-names></name><name><surname>Fernandez-Torron</surname><given-names>R</given-names></name><name><surname>Garcia-Puga</surname><given-names>M</given-names></name><name><surname>Matheu</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Muscle wasting in myotonic dystrophies: a model of premature aging</article-title>. <source/>Front Aging Neurosci (<year>2015</year>) <volume>7</volume>:<fpage>125</fpage>.<pub-id pub-id-type="doi">10.3389/fnagi.2015.00125</pub-id><pub-id pub-id-type="pmid">26217220</pub-id></mixed-citation>
</ref>
<ref id="B28">
<label>28</label>
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bird</surname><given-names>TD</given-names></name></person-group>
<article-title>Myotonic dystrophy type 1</article-title>. In: <person-group person-group-type="editor"><name><surname>Adam</surname><given-names>MP</given-names></name><name><surname>Ardinger</surname><given-names>HH</given-names></name><name><surname>Pagon</surname><given-names>RA</given-names></name><name><surname>Wallace</surname><given-names>SE</given-names></name><name><surname>Bean</surname><given-names>LJH</given-names></name><name><surname>Stephens</surname><given-names>K</given-names></name><etal></etal></person-group> editors. <source/>GeneReviews® [Internet]. <publisher-loc>Seattle, WA</publisher-loc>: <publisher-name>University of Washington</publisher-name>
<fpage>1993</fpage>–<lpage>2018</lpage>.</mixed-citation>
</ref>
<ref id="B29">
<label>29</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liquori</surname><given-names>CL</given-names></name><name><surname>Ricker</surname><given-names>K</given-names></name><name><surname>Moseley</surname><given-names>ML</given-names></name><name><surname>Jacobsen</surname><given-names>JF</given-names></name><name><surname>Kress</surname><given-names>W</given-names></name><name><surname>Naylor</surname><given-names>SL</given-names></name><etal></etal></person-group>
<article-title>Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9</article-title>. <source/>Science (<year>2001</year>) <volume>293</volume>(<issue>5531</issue>):<fpage>864</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1126/science.1062125</pub-id><pub-id pub-id-type="pmid">11486088</pub-id></mixed-citation>
</ref>
<ref id="B30">
<label>30</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Day</surname><given-names>JW</given-names></name><name><surname>Ricker</surname><given-names>K</given-names></name><name><surname>Jacobsen</surname><given-names>JF</given-names></name><name><surname>Rasmussen</surname><given-names>LJ</given-names></name><name><surname>Dick</surname><given-names>KA</given-names></name><name><surname>Kress</surname><given-names>W</given-names></name><etal></etal></person-group>
<article-title>Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum</article-title>. <source/>Neurology (<year>2003</year>) <volume>60</volume>(<issue>4</issue>):<fpage>657</fpage>–<lpage>64</lpage>.<pub-id pub-id-type="doi">10.1212/01.WNL.0000054481.84978.F9</pub-id><pub-id pub-id-type="pmid">12601109</pub-id></mixed-citation>
</ref>
<ref id="B31">
<label>31</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiménez-Moreno</surname><given-names>AC</given-names></name><name><surname>Raaphorst</surname><given-names>J</given-names></name><name><surname>Babačić</surname><given-names>H</given-names></name><name><surname>Wood</surname><given-names>L</given-names></name><name><surname>van Engelen</surname><given-names>B</given-names></name><name><surname>Lochmüller</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Falls and resulting fractures in myotonic dystrophy: results from a multinational retrospective survey</article-title>. <source/>Neuromuscul Disord (<year>2018</year>) <volume>28</volume>(<issue>3</issue>):<fpage>229</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="doi">10.1016/j.nmd.2017.12.010</pub-id><pub-id pub-id-type="pmid">29361394</pub-id></mixed-citation>
</ref>
<ref id="B32">
<label>32</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montagnese</surname><given-names>F</given-names></name><name><surname>Mondello</surname><given-names>S</given-names></name><name><surname>Wenninger</surname><given-names>S</given-names></name><name><surname>Kress</surname><given-names>W</given-names></name><name><surname>Schoser</surname><given-names>B</given-names></name></person-group>. <article-title>Assessing the influence of age and gender on the phenotype of myotonic dystrophy type 2</article-title>. <source/>J Neurol (<year>2017</year>) <volume>264</volume>(<issue>12</issue>):<fpage>2472</fpage>–<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1007/s00415-017-8653-2</pub-id><pub-id pub-id-type="pmid">29086017</pub-id></mixed-citation>
</ref>
<ref id="B33">
<label>33</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricker</surname><given-names>K</given-names></name><name><surname>Koch</surname><given-names>MC</given-names></name><name><surname>Lehmann-Horn</surname><given-names>F</given-names></name><name><surname>Pongratz</surname><given-names>D</given-names></name><name><surname>Otto</surname><given-names>M</given-names></name><name><surname>Heine</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle weakness, and cataracts</article-title>. <source/>Neurology (<year>1994</year>) <volume>44</volume>(<issue>8</issue>):<fpage>1448</fpage>–<lpage>52</lpage>.<pub-id pub-id-type="doi">10.1212/WNL.44.8.1448</pub-id><pub-id pub-id-type="pmid">8058147</pub-id></mixed-citation>
</ref>
<ref id="B34">
<label>34</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kornblum</surname><given-names>C</given-names></name><name><surname>Lutterbey</surname><given-names>G</given-names></name><name><surname>Bogdanow</surname><given-names>M</given-names></name><name><surname>Kesper</surname><given-names>K</given-names></name><name><surname>Schild</surname><given-names>H</given-names></name><name><surname>Schroder</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>Distinct neuromuscular phenotypes in myotonic dystrophy types 1 and 2: a whole body highfield MRI study</article-title>. <source/>J Neurol (<year>2006</year>) <volume>253</volume>(<issue>6</issue>):<fpage>753</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1007/s00415-006-0111-5</pub-id><pub-id pub-id-type="pmid">16511650</pub-id></mixed-citation>
</ref>
<ref id="B35">
<label>35</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stahl</surname><given-names>K</given-names></name><name><surname>Wenninger</surname><given-names>S</given-names></name><name><surname>Schuller</surname><given-names>A</given-names></name><name><surname>Montagnese</surname><given-names>F</given-names></name><name><surname>Schoser</surname><given-names>B</given-names></name></person-group>. <article-title>[Educational and professional qualifications of adults with myotonic dystrophies – a misleading perception by the myopathic face?]</article-title>. <source/>Fortschr Neurol Psychiatr (<year>2016</year>) <volume>84</volume>(<issue>4</issue>):<fpage>211</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1055/s-0042-104193</pub-id><pub-id pub-id-type="pmid">27100845</pub-id></mixed-citation>
</ref>
<ref id="B36">
<label>36</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heatwole</surname><given-names>C</given-names></name><name><surname>Johnson</surname><given-names>N</given-names></name><name><surname>Bode</surname><given-names>R</given-names></name><name><surname>Dekdebrun</surname><given-names>J</given-names></name><name><surname>Dilek</surname><given-names>N</given-names></name><name><surname>Hilbert</surname><given-names>JE</given-names></name><etal></etal></person-group>
<article-title>Patient-reported impact of symptoms in myotonic dystrophy type 2 (PRISM-2)</article-title>. <source/>Neurology (<year>2015</year>) <volume>85</volume>(<issue>24</issue>):<fpage>2136</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="doi">10.1212/WNL.0000000000002225</pub-id><pub-id pub-id-type="pmid">26581301</pub-id></mixed-citation>
</ref>
<ref id="B37">
<label>37</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Swart</surname><given-names>BJ</given-names></name><name><surname>van Engelen</surname><given-names>BG</given-names></name><name><surname>van de Kerkhof</surname><given-names>JP</given-names></name><name><surname>Maassen</surname><given-names>BA</given-names></name></person-group>. <article-title>Myotonia and flaccid dysarthria in patients with adult onset myotonic dystrophy</article-title>. <source/>J Neurol Neurosurg Psychiatry (<year>2004</year>) <volume>75</volume>(<issue>10</issue>):<fpage>1480</fpage>–<lpage>2</lpage>.<pub-id pub-id-type="doi">10.1136/jnnp.2003.032151</pub-id><pub-id pub-id-type="pmid">15377703</pub-id></mixed-citation>
</ref>
<ref id="B38">
<label>38</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Logigian</surname><given-names>EL</given-names></name><name><surname>Blood</surname><given-names>CL</given-names></name><name><surname>Dilek</surname><given-names>N</given-names></name><name><surname>Martens</surname><given-names>WB</given-names></name><name><surname>Moxley</surname><given-names>RT</given-names></name><name><surname>Wiegner</surname><given-names>AW</given-names></name><etal></etal></person-group>
<article-title>Quantitative analysis of the “warm-up” phenomenon in myotonic dystrophy type 1</article-title>. <source/>Muscle Nerve (<year>2005</year>) <volume>32</volume>(<issue>1</issue>):<fpage>35</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1002/mus.20339</pub-id><pub-id pub-id-type="pmid">15880468</pub-id></mixed-citation>
</ref>
<ref id="B39">
<label>39</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hudson</surname><given-names>AJ</given-names></name><name><surname>Ebers</surname><given-names>GC</given-names></name><name><surname>Bulman</surname><given-names>DE</given-names></name></person-group>. <article-title>The skeletal muscle sodium and chloride channel diseases</article-title>. <source/>Brain (<year>1995</year>) <volume>118</volume>(<issue>Pt 2</issue>):<fpage>547</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1093/brain/118.2.547</pub-id><pub-id pub-id-type="pmid">7735894</pub-id></mixed-citation>
</ref>
<ref id="B40">
<label>40</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>NP</given-names></name><name><surname>Daube</surname><given-names>JR</given-names></name><name><surname>Sorenson</surname><given-names>EJ</given-names></name><name><surname>Milone</surname><given-names>M</given-names></name></person-group>. <article-title>Absent, unrecognized, and minimal myotonic discharges in myotonic dystrophy type 2</article-title>. <source/>Muscle Nerve (<year>2010</year>) <volume>41</volume>(<issue>6</issue>):<fpage>758</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1002/mus.21615</pub-id><pub-id pub-id-type="pmid">20513102</pub-id></mixed-citation>
</ref>
<ref id="B41">
<label>41</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meola</surname><given-names>G</given-names></name></person-group>. <article-title>Clinical aspects, molecular pathomechanisms and management of myotonic dystrophies</article-title>. <source/>Acta Myol (<year>2013</year>) <volume>32</volume>(<issue>3</issue>):<fpage>154</fpage>–<lpage>65</lpage>.<pub-id pub-id-type="pmid">24803843</pub-id></mixed-citation>
</ref>
<ref id="B42">
<label>42</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caillet-Boudin</surname><given-names>ML</given-names></name><name><surname>Fernandez-Gomez</surname><given-names>FJ</given-names></name><name><surname>Tran</surname><given-names>H</given-names></name><name><surname>Dhaenens</surname><given-names>CM</given-names></name><name><surname>Buee</surname><given-names>L</given-names></name><name><surname>Sergeant</surname><given-names>N</given-names></name></person-group>. <article-title>Brain pathology in myotonic dystrophy: when tauopathy meets spliceopathy and RNAopathy</article-title>. <source/>Front Mol Neurosci (<year>2014</year>) <volume>6</volume>:<fpage>57</fpage>.<pub-id pub-id-type="doi">10.3389/fnmol.2013.00057</pub-id><pub-id pub-id-type="pmid">24409116</pub-id></mixed-citation>
</ref>
<ref id="B43">
<label>43</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodwin</surname><given-names>M</given-names></name><name><surname>Mohan</surname><given-names>A</given-names></name><name><surname>Batra</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>KY</given-names></name><name><surname>Charizanis</surname><given-names>K</given-names></name><name><surname>Fernandez Gomez</surname><given-names>FJ</given-names></name><etal></etal></person-group>
<article-title>MBNL sequestration by toxic RNAs and RNA misprocessing in the myotonic dystrophy brain</article-title>. <source/>Cell Rep (<year>2015</year>) <volume>12</volume>(<issue>7</issue>):<fpage>1159</fpage>–<lpage>68</lpage>.<pub-id pub-id-type="doi">10.1016/j.celrep.2015.07.029</pub-id><pub-id pub-id-type="pmid">26257173</pub-id></mixed-citation>
</ref>
<ref id="B44">
<label>44</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toth</surname><given-names>A</given-names></name><name><surname>Lovadi</surname><given-names>E</given-names></name><name><surname>Komoly</surname><given-names>S</given-names></name><name><surname>Schwarcz</surname><given-names>A</given-names></name><name><surname>Orsi</surname><given-names>G</given-names></name><name><surname>Perlaki</surname><given-names>G</given-names></name><etal></etal></person-group>
<article-title>Cortical involvement during myotonia in myotonic dystrophy: an fMRI study</article-title>. <source/>Acta Neurol Scand (<year>2015</year>) <volume>132</volume>(<issue>1</issue>):<fpage>65</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="doi">10.1111/ane.12360</pub-id><pub-id pub-id-type="pmid">25630356</pub-id></mixed-citation>
</ref>
<ref id="B45">
<label>45</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanigni</surname><given-names>S</given-names></name><name><surname>Evangelisti</surname><given-names>S</given-names></name><name><surname>Giannoccaro</surname><given-names>MP</given-names></name><name><surname>Oppi</surname><given-names>F</given-names></name><name><surname>Poda</surname><given-names>R</given-names></name><name><surname>Giorgio</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Relationship of white and gray matter abnormalities to clinical and genetic features in myotonic dystrophy type 1</article-title>. <source/>Neuroimage Clin (<year>2016</year>) <volume>11</volume>:<fpage>678</fpage>–<lpage>85</lpage>.<pub-id pub-id-type="doi">10.1016/j.nicl.2016.04.012</pub-id><pub-id pub-id-type="pmid">27330968</pub-id></mixed-citation>
</ref>
<ref id="B46">
<label>46</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>G</given-names></name><name><surname>Orngreen</surname><given-names>MC</given-names></name><name><surname>Preisler</surname><given-names>N</given-names></name><name><surname>Colding-Jorgensen</surname><given-names>E</given-names></name><name><surname>Clausen</surname><given-names>T</given-names></name><name><surname>Duno</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Muscle phenotype in patients with myotonic dystrophy type 1</article-title>. <source/>Muscle Nerve (<year>2013</year>) <volume>47</volume>(<issue>3</issue>):<fpage>409</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="doi">10.1002/mus.23535</pub-id><pub-id pub-id-type="pmid">23169601</pub-id></mixed-citation>
</ref>
<ref id="B47">
<label>47</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogrel</surname><given-names>JY</given-names></name><name><surname>Ollivier</surname><given-names>G</given-names></name><name><surname>Ledoux</surname><given-names>I</given-names></name><name><surname>Hebert</surname><given-names>LJ</given-names></name><name><surname>Eymard</surname><given-names>B</given-names></name><name><surname>Puymirat</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Relationships between grip strength, myotonia, and CTG expansion in myotonic dystrophy type 1</article-title>. <source/>Ann Clin Transl Neurol (<year>2017</year>) <volume>4</volume>(<issue>12</issue>):<fpage>921</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1002/acn3.496</pub-id><pub-id pub-id-type="pmid">29296622</pub-id></mixed-citation>
</ref>
<ref id="B48">
<label>48</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardani</surname><given-names>R</given-names></name><name><surname>Giagnacovo</surname><given-names>M</given-names></name><name><surname>Botta</surname><given-names>A</given-names></name><name><surname>Rinaldi</surname><given-names>F</given-names></name><name><surname>Morgante</surname><given-names>A</given-names></name><name><surname>Udd</surname><given-names>B</given-names></name><etal></etal></person-group>
<article-title>Co-segregation of DM2 with a recessive CLCN1 mutation in juvenile onset of myotonic dystrophy type 2</article-title>. <source/>J Neurol (<year>2012</year>) <volume>259</volume>(<issue>10</issue>):<fpage>2090</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1007/s00415-012-6462-1</pub-id><pub-id pub-id-type="pmid">22407275</pub-id></mixed-citation>
</ref>
<ref id="B49">
<label>49</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bugiardini</surname><given-names>E</given-names></name><name><surname>Rivolta</surname><given-names>I</given-names></name><name><surname>Binda</surname><given-names>A</given-names></name><name><surname>Soriano Caminero</surname><given-names>A</given-names></name><name><surname>Cirillo</surname><given-names>F</given-names></name><name><surname>Cinti</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>SCN4A mutation as modifying factor of myotonic dystrophy type 2 phenotype</article-title>. <source/>Neuromuscul Disord (<year>2015</year>) <volume>25</volume>(<issue>4</issue>):<fpage>301</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/j.nmd.2015.01.006</pub-id><pub-id pub-id-type="pmid">25660391</pub-id></mixed-citation>
</ref>
<ref id="B50">
<label>50</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rakocevic Stojanovic</surname><given-names>V</given-names></name><name><surname>Peric</surname><given-names>S</given-names></name><name><surname>Paunic</surname><given-names>T</given-names></name><name><surname>Pesovic</surname><given-names>J</given-names></name><name><surname>Vujnic</surname><given-names>M</given-names></name><name><surname>Peric</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Quality of life in patients with myotonic dystrophy type 2</article-title>. <source/>J Neurol Sci (<year>2016</year>) <volume>365</volume>:<fpage>158</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1016/j.jns.2016.04.018</pub-id><pub-id pub-id-type="pmid">27206898</pub-id></mixed-citation>
</ref>
<ref id="B51">
<label>51</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suokas</surname><given-names>KI</given-names></name><name><surname>Haanpaa</surname><given-names>M</given-names></name><name><surname>Kautiainen</surname><given-names>H</given-names></name><name><surname>Udd</surname><given-names>B</given-names></name><name><surname>Hietaharju</surname><given-names>AJ</given-names></name></person-group>. <article-title>Pain in patients with myotonic dystrophy type 2: a postal survey in Finland</article-title>. <source/>Muscle Nerve (<year>2012</year>) <volume>45</volume>(<issue>1</issue>):<fpage>70</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1002/mus.22249</pub-id><pub-id pub-id-type="pmid">22190310</pub-id></mixed-citation>
</ref>
<ref id="B52">
<label>52</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moshourab</surname><given-names>R</given-names></name><name><surname>Palada</surname><given-names>V</given-names></name><name><surname>Grunwald</surname><given-names>S</given-names></name><name><surname>Grieben</surname><given-names>U</given-names></name><name><surname>Lewin</surname><given-names>GR</given-names></name><name><surname>Spuler</surname><given-names>S</given-names></name></person-group>. <article-title>A molecular signature of myalgia in myotonic dystrophy 2</article-title>. <source/>EBioMedicine (<year>2016</year>) <volume>7</volume>:<fpage>205</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="doi">10.1016/j.ebiom.2016.03.017</pub-id><pub-id pub-id-type="pmid">27322473</pub-id></mixed-citation>
</ref>
<ref id="B53">
<label>53</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reardon</surname><given-names>W</given-names></name><name><surname>Newcombe</surname><given-names>R</given-names></name><name><surname>Fenton</surname><given-names>I</given-names></name><name><surname>Sibert</surname><given-names>J</given-names></name><name><surname>Harper</surname><given-names>PS</given-names></name></person-group>. <article-title>The natural history of congenital myotonic dystrophy: mortality and long term clinical aspects</article-title>. <source/>Arch Dis Child (<year>1993</year>) <volume>68</volume>(<issue>2</issue>):<fpage>177</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1136/adc.68.2.177</pub-id><pub-id pub-id-type="pmid">8481038</pub-id></mixed-citation>
</ref>
<ref id="B54">
<label>54</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boentert</surname><given-names>M</given-names></name><name><surname>Wenninger</surname><given-names>S</given-names></name><name><surname>Sansone</surname><given-names>VA</given-names></name></person-group>. <article-title>Respiratory involvement in neuromuscular disorders</article-title>. <source/>Curr Opin Neurol (<year>2017</year>) <volume>30</volume>(<issue>5</issue>):<fpage>529</fpage>–<lpage>37</lpage>.<pub-id pub-id-type="doi">10.1097/WCO.0000000000000470</pub-id><pub-id pub-id-type="pmid">28562381</pub-id></mixed-citation>
</ref>
<ref id="B55">
<label>55</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sansone</surname><given-names>VA</given-names></name><name><surname>Gagnon</surname><given-names>C</given-names></name></person-group>
<article-title>207th ENMC Workshop on chronic respiratory insufficiency in myotonic dystrophies: management and implications for research, 27-29 June 2014, Naarden, The Netherlands</article-title>. <source/>Neuromuscul Disord (<year>2015</year>) <volume>25</volume>(<issue>5</issue>):<fpage>432</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1016/j.nmd.2015.01.011</pub-id><pub-id pub-id-type="pmid">25728518</pub-id></mixed-citation>
</ref>
<ref id="B56">
<label>56</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modoni</surname><given-names>A</given-names></name><name><surname>Silvestri</surname><given-names>G</given-names></name><name><surname>Pomponi</surname><given-names>MG</given-names></name><name><surname>Mangiola</surname><given-names>F</given-names></name><name><surname>Tonali</surname><given-names>PA</given-names></name><name><surname>Marra</surname><given-names>C</given-names></name></person-group>. <article-title>Characterization of the pattern of cognitive impairment in myotonic dystrophy type 1</article-title>. <source/>Arch Neurol (<year>2004</year>) <volume>61</volume>(<issue>12</issue>):<fpage>1943</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1001/archneur.61.12.1943</pub-id><pub-id pub-id-type="pmid">15596617</pub-id></mixed-citation>
</ref>
<ref id="B57">
<label>57</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winblad</surname><given-names>S</given-names></name><name><surname>Lindberg</surname><given-names>C</given-names></name><name><surname>Hansen</surname><given-names>S</given-names></name></person-group>
<article-title>Cognitive deficits and CTG repeat expansion size in classical myotonic dystrophy type 1 (DM1)</article-title>. <source/>Behav Brain Funct (<year>2006</year>) <volume>2</volume>:<fpage>16</fpage><pub-id pub-id-type="doi">10.1186/1744-9081-2-16</pub-id><pub-id pub-id-type="pmid">16696870</pub-id></mixed-citation>
</ref>
<ref id="B58">
<label>58</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugiyama</surname><given-names>A</given-names></name><name><surname>Sone</surname><given-names>D</given-names></name><name><surname>Sato</surname><given-names>N</given-names></name><name><surname>Kimura</surname><given-names>Y</given-names></name><name><surname>Ota</surname><given-names>M</given-names></name><name><surname>Maikusa</surname><given-names>N</given-names></name><etal></etal></person-group>
<article-title>Brain gray matter structural network in myotonic dystrophy type 1</article-title>. <source/>PLoS One (<year>2017</year>) <volume>12</volume>(<issue>11</issue>):<fpage>e0187343</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0187343</pub-id><pub-id pub-id-type="pmid">29095898</pub-id></mixed-citation>
</ref>
<ref id="B59">
<label>59</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minnerop</surname><given-names>M</given-names></name><name><surname>Weber</surname><given-names>B</given-names></name><name><surname>Schoene-Bake</surname><given-names>JC</given-names></name><name><surname>Roeske</surname><given-names>S</given-names></name><name><surname>Mirbach</surname><given-names>S</given-names></name><name><surname>Anspach</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title>The brain in myotonic dystrophy 1 and 2: evidence for a predominant white matter disease</article-title>. <source/>Brain (<year>2011</year>) <volume>134</volume>(<issue>Pt 12</issue>):<fpage>3530</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="doi">10.1093/brain/awr299</pub-id><pub-id pub-id-type="pmid">22131273</pub-id></mixed-citation>
</ref>
<ref id="B60">
<label>60</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caso</surname><given-names>F</given-names></name><name><surname>Agosta</surname><given-names>F</given-names></name><name><surname>Peric</surname><given-names>S</given-names></name><name><surname>Rakocevic-Stojanovic</surname><given-names>V</given-names></name><name><surname>Copetti</surname><given-names>M</given-names></name><name><surname>Kostic</surname><given-names>VS</given-names></name><etal></etal></person-group>
<article-title>Cognitive impairment in myotonic dystrophy type 1 is associated with white matter damage</article-title>. <source/>PLoS One (<year>2014</year>) <volume>9</volume>(<issue>8</issue>):<fpage>e104697</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0104697</pub-id><pub-id pub-id-type="pmid">25115999</pub-id></mixed-citation>
</ref>
<ref id="B61">
<label>61</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kornblum</surname><given-names>C</given-names></name><name><surname>Reul</surname><given-names>J</given-names></name><name><surname>Kress</surname><given-names>W</given-names></name><name><surname>Grothe</surname><given-names>C</given-names></name><name><surname>Amanatidis</surname><given-names>N</given-names></name><name><surname>Klockgether</surname><given-names>T</given-names></name><etal></etal></person-group>
<article-title>Cranial magnetic resonance imaging in genetically proven myotonic dystrophy type 1 and 2</article-title>. <source/>J Neurol (<year>2004</year>) <volume>251</volume>(<issue>6</issue>):<fpage>710</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1007/s00415-004-0408-1</pub-id><pub-id pub-id-type="pmid">15311347</pub-id></mixed-citation>
</ref>
<ref id="B62">
<label>62</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franc</surname><given-names>DT</given-names></name><name><surname>Muetzel</surname><given-names>RL</given-names></name><name><surname>Robinson</surname><given-names>PR</given-names></name><name><surname>Rodriguez</surname><given-names>CP</given-names></name><name><surname>Dalton</surname><given-names>JC</given-names></name><name><surname>Naughton</surname><given-names>CE</given-names></name><etal></etal></person-group>
<article-title>Cerebral and muscle MRI abnormalities in myotonic dystrophy</article-title>. <source/>Neuromuscul Disord (<year>2012</year>) <volume>22</volume>(<issue>6</issue>):<fpage>483</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1016/j.nmd.2012.01.003</pub-id><pub-id pub-id-type="pmid">22290140</pub-id></mixed-citation>
</ref>
<ref id="B63">
<label>63</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider-Gold</surname><given-names>C</given-names></name><name><surname>Bellenberg</surname><given-names>B</given-names></name><name><surname>Prehn</surname><given-names>C</given-names></name><name><surname>Krogias</surname><given-names>C</given-names></name><name><surname>Schneider</surname><given-names>R</given-names></name><name><surname>Klein</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Cortical and subcortical grey and white matter atrophy in myotonic dystrophies type 1 and 2 is associated with cognitive impairment, depression and daytime sleepiness</article-title>. <source/>PLoS One (<year>2015</year>) <volume>10</volume>(<issue>6</issue>):<fpage>e0130352</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0130352</pub-id><pub-id pub-id-type="pmid">26114298</pub-id></mixed-citation>
</ref>
<ref id="B64">
<label>64</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meola</surname><given-names>G</given-names></name><name><surname>Sansone</surname><given-names>V</given-names></name><name><surname>Perani</surname><given-names>D</given-names></name><name><surname>Scarone</surname><given-names>S</given-names></name><name><surname>Cappa</surname><given-names>S</given-names></name><name><surname>Dragoni</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title>Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM-1) and in proximal myotonic myopathy (PROMM/DM-2)</article-title>. <source/>Neuromuscul Disord (<year>2003</year>) <volume>13</volume>(<issue>10</issue>):<fpage>813</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="doi">10.1016/S0960-8966(03)00137-8</pub-id><pub-id pub-id-type="pmid">14678804</pub-id></mixed-citation>
</ref>
<ref id="B65">
<label>65</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bianchi</surname><given-names>ML</given-names></name><name><surname>Losurdo</surname><given-names>A</given-names></name><name><surname>Di Blasi</surname><given-names>C</given-names></name><name><surname>Santoro</surname><given-names>M</given-names></name><name><surname>Masciullo</surname><given-names>M</given-names></name><name><surname>Conte</surname><given-names>G</given-names></name><etal></etal></person-group>
<article-title>Prevalence and clinical correlates of sleep disordered breathing in myotonic dystrophy types 1 and 2</article-title>. <source/>Sleep Breath (<year>2014</year>) <volume>18</volume>(<issue>3</issue>):<fpage>579</fpage>–<lpage>89</lpage>.<pub-id pub-id-type="doi">10.1007/s11325-013-0921-5</pub-id><pub-id pub-id-type="pmid">24310756</pub-id></mixed-citation>
</ref>
<ref id="B66">
<label>66</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>G</given-names></name><name><surname>Widger</surname><given-names>J</given-names></name><name><surname>Cardamone</surname><given-names>M</given-names></name><name><surname>Farrar</surname><given-names>MA</given-names></name></person-group>. <article-title>Quality of life and excessive daytime sleepiness in children and adolescents with myotonic dystrophy type 1</article-title>. <source/>Sleep Med (<year>2017</year>) <volume>32</volume>:<fpage>92</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/j.sleep.2016.12.005</pub-id><pub-id pub-id-type="pmid">28366348</pub-id></mixed-citation>
</ref>
<ref id="B67">
<label>67</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gourdon</surname><given-names>G</given-names></name><name><surname>Meola</surname><given-names>G</given-names></name></person-group>. <article-title>Myotonic dystrophies: state of the art of new therapeutic developments for the CNS</article-title>. <source/>Front Cell Neurosci (<year>2017</year>) <volume>11</volume>:<fpage>101</fpage>.<pub-id pub-id-type="doi">10.3389/fncel.2017.00101</pub-id><pub-id pub-id-type="pmid">28473756</pub-id></mixed-citation>
</ref>
<ref id="B68">
<label>68</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itoh</surname><given-names>K</given-names></name><name><surname>Mitani</surname><given-names>M</given-names></name><name><surname>Kawamoto</surname><given-names>K</given-names></name><name><surname>Futamura</surname><given-names>N</given-names></name><name><surname>Funakawa</surname><given-names>I</given-names></name><name><surname>Jinnai</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>Neuropathology does not correlate with regional differences in the extent of expansion of CTG repeats in the brain with myotonic dystrophy type 1</article-title>. <source/>Acta Histochem Cytochem (<year>2010</year>) <volume>43</volume>(<issue>6</issue>):<fpage>149</fpage>–<lpage>56</lpage>.<pub-id pub-id-type="doi">10.1267/ahc.10019</pub-id><pub-id pub-id-type="pmid">21245981</pub-id></mixed-citation>
</ref>
<ref id="B69">
<label>69</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekstrom</surname><given-names>AB</given-names></name><name><surname>Tulinius</surname><given-names>M</given-names></name><name><surname>Sjostrom</surname><given-names>A</given-names></name><name><surname>Aring</surname><given-names>E</given-names></name></person-group>. <article-title>Visual function in congenital and childhood myotonic dystrophy type 1</article-title>. <source/>Ophthalmology (<year>2010</year>) <volume>117</volume>(<issue>5</issue>):<fpage>976</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="doi">10.1016/j.ophtha.2010.01.055</pub-id><pub-id pub-id-type="pmid">20346513</pub-id></mixed-citation>
</ref>
<ref id="B70">
<label>70</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunner</surname><given-names>HG</given-names></name><name><surname>Nillesen</surname><given-names>W</given-names></name><name><surname>van Oost</surname><given-names>BA</given-names></name><name><surname>Jansen</surname><given-names>G</given-names></name><name><surname>Wieringa</surname><given-names>B</given-names></name><name><surname>Ropers</surname><given-names>HH</given-names></name><etal></etal></person-group>
<article-title>Presymptomatic diagnosis of myotonic dystrophy</article-title>. <source/>J Med Genet (<year>1992</year>) <volume>29</volume>(<issue>11</issue>):<fpage>780</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1136/jmg.29.11.780</pub-id><pub-id pub-id-type="pmid">1453426</pub-id></mixed-citation>
</ref>
<ref id="B71">
<label>71</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kidd</surname><given-names>A</given-names></name><name><surname>Turnpenny</surname><given-names>P</given-names></name><name><surname>Kelly</surname><given-names>K</given-names></name><name><surname>Clark</surname><given-names>C</given-names></name><name><surname>Church</surname><given-names>W</given-names></name><name><surname>Hutchinson</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title>Ascertainment of myotonic dystrophy through cataract by selective screening</article-title>. <source/>J Med Genet (<year>1995</year>) <volume>32</volume>(<issue>7</issue>):<fpage>519</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1136/jmg.32.7.519</pub-id><pub-id pub-id-type="pmid">7562963</pub-id></mixed-citation>
</ref>
<ref id="B72">
<label>72</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rakocevic-Stojanovic</surname><given-names>V</given-names></name><name><surname>Peric</surname><given-names>S</given-names></name><name><surname>Pesovic</surname><given-names>J</given-names></name><name><surname>Sencanic</surname><given-names>I</given-names></name><name><surname>Bozic</surname><given-names>M</given-names></name><name><surname>Svikovic</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Genetic testing of individuals with pre-senile cataract identifies patients with myotonic dystrophy type 2</article-title>. <source/>Eur J Neurol (<year>2017</year>) <volume>24</volume>(<issue>11</issue>):<fpage>e79</fpage>–<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1111/ene.13401</pub-id><pub-id pub-id-type="pmid">29024355</pub-id></mixed-citation>
</ref>
<ref id="B73">
<label>73</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Cho</surname><given-names>DH</given-names></name><name><surname>Tapscott</surname><given-names>SJ</given-names></name><name><surname>Ozaki</surname><given-names>H</given-names></name><name><surname>Kawakami</surname><given-names>K</given-names></name></person-group>. <article-title>Identification of transcriptional targets for Six5: implication for the pathogenesis of myotonic dystrophy type 1</article-title>. <source/>Hum Mol Genet (<year>2002</year>) <volume>11</volume>(<issue>9</issue>):<fpage>1045</fpage>–<lpage>58</lpage>.<pub-id pub-id-type="doi">10.1093/hmg/11.9.1045</pub-id><pub-id pub-id-type="pmid">11978764</pub-id></mixed-citation>
</ref>
<ref id="B74">
<label>74</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhodes</surname><given-names>JD</given-names></name><name><surname>Lott</surname><given-names>MC</given-names></name><name><surname>Russell</surname><given-names>SL</given-names></name><name><surname>Moulton</surname><given-names>V</given-names></name><name><surname>Sanderson</surname><given-names>J</given-names></name><name><surname>Wormstone</surname><given-names>IM</given-names></name><etal></etal></person-group>
<article-title>Activation of the innate immune response and interferon signalling in myotonic dystrophy type 1 and type 2 cataracts</article-title>. <source/>Hum Mol Genet (<year>2012</year>) <volume>21</volume>(<issue>4</issue>):<fpage>852</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1093/hmg/ddr515</pub-id><pub-id pub-id-type="pmid">22062891</pub-id></mixed-citation>
</ref>
<ref id="B75">
<label>75</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shao</surname><given-names>D</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Huo</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Investigation of the molecular mechanisms underlying myotonic dystrophy types 1 and 2 cataracts using microRNAtarget gene networks</article-title>. <source/>Mol Med Rep (<year>2017</year>) <volume>16</volume>(<issue>4</issue>):<fpage>3737</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="doi">10.3892/mmr.2017.7059</pub-id><pub-id pub-id-type="pmid">28731161</pub-id></mixed-citation>
</ref>
<ref id="B76">
<label>76</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passeri</surname><given-names>E</given-names></name><name><surname>Bugiardini</surname><given-names>E</given-names></name><name><surname>Sansone</surname><given-names>VA</given-names></name><name><surname>Valaperta</surname><given-names>R</given-names></name><name><surname>Costa</surname><given-names>E</given-names></name><name><surname>Ambrosi</surname><given-names>B</given-names></name><etal></etal></person-group>
<article-title>Vitamin D, parathyroid hormone and muscle impairment in myotonic dystrophies</article-title>. <source/>J Neurol Sci (<year>2013</year>) <volume>331</volume>(<issue>1–2</issue>):<fpage>132</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1016/j.jns.2013.06.008</pub-id><pub-id pub-id-type="pmid">23809192</pub-id></mixed-citation>
</ref>
<ref id="B77">
<label>77</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terracciano</surname><given-names>C</given-names></name><name><surname>Rastelli</surname><given-names>E</given-names></name><name><surname>Morello</surname><given-names>M</given-names></name><name><surname>Celi</surname><given-names>M</given-names></name><name><surname>Bucci</surname><given-names>E</given-names></name><name><surname>Antonini</surname><given-names>G</given-names></name><etal></etal></person-group>
<article-title>Vitamin D deficiency in myotonic dystrophy type 1</article-title>. <source/>J Neurol (<year>2013</year>) <volume>260</volume>(<issue>9</issue>):<fpage>2330</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1007/s00415-013-6984-1</pub-id><pub-id pub-id-type="pmid">23754696</pub-id></mixed-citation>
</ref>
<ref id="B78">
<label>78</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahlqvist</surname><given-names>JR</given-names></name><name><surname>Orngreen</surname><given-names>MC</given-names></name><name><surname>Witting</surname><given-names>N</given-names></name><name><surname>Vissing</surname><given-names>J</given-names></name></person-group>. <article-title>Endocrine function over time in patients with myotonic dystrophy type 1</article-title>. <source/>Eur J Neurol (<year>2015</year>) <volume>22</volume>(<issue>1</issue>):<fpage>116</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1111/ene.12542</pub-id><pub-id pub-id-type="pmid">25155546</pub-id></mixed-citation>
</ref>
<ref id="B79">
<label>79</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumura</surname><given-names>T</given-names></name><name><surname>Iwahashi</surname><given-names>H</given-names></name><name><surname>Funahashi</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>MP</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Yasui</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>A cross-sectional study for glucose intolerance of myotonic dystrophy</article-title>. <source/>J Neurol Sci (<year>2009</year>) <volume>276</volume>(<issue>1–2</issue>):<fpage>60</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1016/j.jns.2008.08.037</pub-id><pub-id pub-id-type="pmid">18834994</pub-id></mixed-citation>
</ref>
<ref id="B80">
<label>80</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thornton</surname><given-names>CA</given-names></name><name><surname>Griggs</surname><given-names>RC</given-names></name><name><surname>Moxley</surname><given-names>RT</given-names><suffix>III</suffix></name></person-group>. <article-title>Myotonic dystrophy with no trinucleotide repeat expansion</article-title>. <source/>Ann Neurol (<year>1994</year>) <volume>35</volume>(<issue>3</issue>):<fpage>269</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="doi">10.1002/ana.410350305</pub-id><pub-id pub-id-type="pmid">8122879</pub-id></mixed-citation>
</ref>
<ref id="B81">
<label>81</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Vliet</surname><given-names>J</given-names></name><name><surname>Tieleman</surname><given-names>AA</given-names></name><name><surname>van Engelen</surname><given-names>BGM</given-names></name><name><surname>Bassez</surname><given-names>G</given-names></name><name><surname>Servais</surname><given-names>L</given-names></name><name><surname>Behin</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Hearing impairment in patients with myotonic dystrophy type 2</article-title>. <source/>Neurology (<year>2018</year>) <volume>90</volume>(<issue>7</issue>):<fpage>e615</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1212/WNL.0000000000004963</pub-id><pub-id pub-id-type="pmid">29343467</pub-id></mixed-citation>
</ref>
<ref id="B82">
<label>82</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pisani</surname><given-names>V</given-names></name><name><surname>Tirabasso</surname><given-names>A</given-names></name><name><surname>Mazzone</surname><given-names>S</given-names></name><name><surname>Terracciano</surname><given-names>C</given-names></name><name><surname>Botta</surname><given-names>A</given-names></name><name><surname>Novelli</surname><given-names>G</given-names></name><etal></etal></person-group>
<article-title>Early subclinical cochlear dysfunction in myotonic dystrophy type 1</article-title>. <source/>Eur J Neurol (<year>2011</year>) <volume>18</volume>(<issue>12</issue>):<fpage>1412</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1111/j.1468-1331.2011.03470.x</pub-id><pub-id pub-id-type="pmid">21777352</pub-id></mixed-citation>
</ref>
<ref id="B83">
<label>83</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bassez</surname><given-names>G</given-names></name><name><surname>Lazarus</surname><given-names>A</given-names></name><name><surname>Desguerre</surname><given-names>I</given-names></name><name><surname>Varin</surname><given-names>J</given-names></name><name><surname>Laforet</surname><given-names>P</given-names></name><name><surname>Becane</surname><given-names>HM</given-names></name><etal></etal></person-group>
<article-title>Severe cardiac arrhythmias in young patients with myotonic dystrophy type 1</article-title>. <source/>Neurology (<year>2004</year>) <volume>63</volume>(<issue>10</issue>):<fpage>1939</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1212/01.WNL.0000144343.91136.CF</pub-id><pub-id pub-id-type="pmid">15557517</pub-id></mixed-citation>
</ref>
<ref id="B84">
<label>84</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wahbi</surname><given-names>K</given-names></name><name><surname>Algalarrondo</surname><given-names>V</given-names></name><name><surname>Becane</surname><given-names>HM</given-names></name><name><surname>Fressart</surname><given-names>V</given-names></name><name><surname>Beldjord</surname><given-names>C</given-names></name><name><surname>Azibi</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>Brugada syndrome and abnormal splicing of SCN5A in myotonic dystrophy type 1</article-title>. <source/>Arch Cardiovasc Dis (<year>2013</year>) <volume>106</volume>(<issue>12</issue>):<fpage>635</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="doi">10.1016/j.acvd.2013.08.003</pub-id><pub-id pub-id-type="pmid">24140416</pub-id></mixed-citation>
</ref>
<ref id="B85">
<label>85</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sansone</surname><given-names>VA</given-names></name><name><surname>Brigonzi</surname><given-names>E</given-names></name><name><surname>Schoser</surname><given-names>B</given-names></name><name><surname>Villani</surname><given-names>S</given-names></name><name><surname>Gaeta</surname><given-names>M</given-names></name><name><surname>De Ambroggi</surname><given-names>G</given-names></name><etal></etal></person-group>
<article-title>The frequency and severity of cardiac involvement in myotonic dystrophy type 2 (DM2): long-term outcomes</article-title>. <source/>Int J Cardiol (<year>2013</year>) <volume>168</volume>(<issue>2</issue>):<fpage>1147</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="doi">10.1016/j.ijcard.2012.11.076</pub-id><pub-id pub-id-type="pmid">23266299</pub-id></mixed-citation>
</ref>
<ref id="B86">
<label>86</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chong-Nguyen</surname><given-names>C</given-names></name><name><surname>Wahbi</surname><given-names>K</given-names></name><name><surname>Algalarrondo</surname><given-names>V</given-names></name><name><surname>Becane</surname><given-names>HM</given-names></name><name><surname>Radvanyi-Hoffman</surname><given-names>H</given-names></name><name><surname>Arnaud</surname><given-names>P</given-names></name><etal></etal></person-group>
<article-title>Association between mutation size and cardiac involvement in myotonic dystrophy type 1: an analysis of the DM1-Heart Registry</article-title>. <source/>Circ Cardiovasc Genet (<year>2017</year>) <volume>10</volume>(<issue>3</issue>):<fpage>e001526</fpage>.<pub-id pub-id-type="doi">10.1161/CIRCGENETICS.116.001526</pub-id><pub-id pub-id-type="pmid">28611030</pub-id></mixed-citation>
</ref>
<ref id="B87">
<label>87</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>K</given-names></name><name><surname>Aburakawa</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Kuroda</surname><given-names>K</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name></person-group>. <article-title>The frequency and risk factors for ischemic stroke in myotonic dystrophy type 1 patients</article-title>. <source/>J Stroke Cerebrovasc Dis (<year>2018</year>) <volume>27</volume>(<issue>4</issue>):<fpage>914</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.jstrokecerebrovasdis.2017.10.030</pub-id><pub-id pub-id-type="pmid">29306591</pub-id></mixed-citation>
</ref>
<ref id="B88">
<label>88</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ronnemaa</surname><given-names>T</given-names></name><name><surname>Alaranta</surname><given-names>H</given-names></name><name><surname>Viikari</surname><given-names>J</given-names></name><name><surname>Tilvis</surname><given-names>R</given-names></name><name><surname>Falck</surname><given-names>B</given-names></name></person-group>. <article-title>Increased activity of serum gamma-glutamyltransferase in myotonic dystrophy</article-title>. <source/>Acta Med Scand (<year>1987</year>) <volume>222</volume>(<issue>3</issue>):<fpage>267</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="doi">10.1111/j.0954-6820.1987.tb10669.x</pub-id><pub-id pub-id-type="pmid">2892348</pub-id></mixed-citation>
</ref>
<ref id="B89">
<label>89</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalafateli</surname><given-names>M</given-names></name><name><surname>Triantos</surname><given-names>C</given-names></name><name><surname>Tsamandas</surname><given-names>A</given-names></name><name><surname>Kounadis</surname><given-names>G</given-names></name><name><surname>Labropoulou-Karatza</surname><given-names>C</given-names></name></person-group>. <article-title>Abnormal liver function tests in a patient with myotonic dystrophy type 1</article-title>. <source/>Ann Hepatol (<year>2012</year>) <volume>11</volume>(<issue>1</issue>):<fpage>130</fpage>–<lpage>3</lpage>.<pub-id pub-id-type="pmid">22166572</pub-id></mixed-citation>
</ref>
<ref id="B90">
<label>90</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunner</surname><given-names>HG</given-names></name><name><surname>Hamel</surname><given-names>BC</given-names></name><name><surname>Rieu</surname><given-names>P</given-names></name><name><surname>Howeler</surname><given-names>CJ</given-names></name><name><surname>Peters</surname><given-names>FT</given-names></name></person-group>
<article-title>Intestinal pseudo-obstruction in myotonic dystrophy</article-title>. <source/>J Med Genet (<year>1992</year>) <volume>29</volume>(<issue>11</issue>):<fpage>791</fpage>–<lpage>3</lpage>.<pub-id pub-id-type="doi">10.1136/jmg.29.11.791</pub-id><pub-id pub-id-type="pmid">1453429</pub-id></mixed-citation>
</ref>
<ref id="B91">
<label>91</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellini</surname><given-names>M</given-names></name><name><surname>Biagi</surname><given-names>S</given-names></name><name><surname>Stasi</surname><given-names>C</given-names></name><name><surname>Costa</surname><given-names>F</given-names></name><name><surname>Mumolo</surname><given-names>MG</given-names></name><name><surname>Ricchiuti</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Gastrointestinal manifestations in myotonic muscular dystrophy</article-title>. <source/>World J Gastroenterol (<year>2006</year>) <volume>12</volume>(<issue>12</issue>):<fpage>1821</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.3748/wjg.v12.i12.1821</pub-id><pub-id pub-id-type="pmid">16609987</pub-id></mixed-citation>
</ref>
<ref id="B92">
<label>92</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ercolin</surname><given-names>B</given-names></name><name><surname>Sassi</surname><given-names>FC</given-names></name><name><surname>Mangilli</surname><given-names>LD</given-names></name><name><surname>Mendonca</surname><given-names>LI</given-names></name><name><surname>Limongi</surname><given-names>SC</given-names></name><name><surname>de Andrade</surname><given-names>CR</given-names></name></person-group>. <article-title>Oral motor movements and swallowing in patients with myotonic dystrophy type 1</article-title>. <source/>Dysphagia (<year>2013</year>) <volume>28</volume>(<issue>3</issue>):<fpage>446</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1007/s00455-013-9458-9</pub-id><pub-id pub-id-type="pmid">23460343</pub-id></mixed-citation>
</ref>
<ref id="B93">
<label>93</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>HI</given-names></name><name><surname>Sheft</surname><given-names>DJ</given-names></name></person-group>
<article-title>Esophageal and colon changes in myotonia dystrophica</article-title>. <source/>Gastroenterology (<year>1972</year>) <volume>63</volume>(<issue>1</issue>):<fpage>134</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">4560193</pub-id></mixed-citation>
</ref>
<ref id="B94">
<label>94</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gadalla</surname><given-names>SM</given-names></name><name><surname>Lund</surname><given-names>M</given-names></name><name><surname>Pfeiffer</surname><given-names>RM</given-names></name><name><surname>Gortz</surname><given-names>S</given-names></name><name><surname>Mueller</surname><given-names>CM</given-names></name><name><surname>Moxley</surname><given-names>RT</given-names><suffix>III</suffix></name><etal></etal></person-group>
<article-title>Cancer risk among patients with myotonic muscular dystrophy</article-title>. <source/>JAMA (<year>2011</year>) <volume>306</volume>(<issue>22</issue>):<fpage>2480</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1001/jama.2011.1796</pub-id><pub-id pub-id-type="pmid">22166607</pub-id></mixed-citation>
</ref>
<ref id="B95">
<label>95</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Win</surname><given-names>AK</given-names></name><name><surname>Perattur</surname><given-names>PG</given-names></name><name><surname>Pulido</surname><given-names>JS</given-names></name><name><surname>Pulido</surname><given-names>CM</given-names></name><name><surname>Lindor</surname><given-names>NM</given-names></name></person-group>. <article-title>Increased cancer risks in myotonic dystrophy</article-title>. <source/>Mayo Clin Proc (<year>2012</year>) <volume>87</volume>(<issue>2</issue>):<fpage>130</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1016/j.mayocp.2011.09.005</pub-id><pub-id pub-id-type="pmid">22237010</pub-id></mixed-citation>
</ref>
<ref id="B96">
<label>96</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alsaggaf</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Marini-Bettolo</surname><given-names>C</given-names></name><name><surname>Wood</surname><given-names>L</given-names></name><name><surname>Nikolenko</surname><given-names>N</given-names></name><name><surname>Lochmuller</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Benign and malignant tumors in the UK myotonic dystrophy patient registry</article-title>. <source/>Muscle Nerve (<year>2018</year>) <volume>57</volume>(<issue>2</issue>):<fpage>316</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1002/mus.25736</pub-id><pub-id pub-id-type="pmid">28662292</pub-id></mixed-citation>
</ref>
<ref id="B97">
<label>97</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peric</surname><given-names>S</given-names></name><name><surname>Stojanovic</surname><given-names>VR</given-names></name><name><surname>Nikolic</surname><given-names>A</given-names></name><name><surname>Kacar</surname><given-names>A</given-names></name><name><surname>Basta</surname><given-names>I</given-names></name><name><surname>Pavlovic</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Peripheral neuropathy in patients with myotonic dystrophy type 1</article-title>. <source/>Neurol Res (<year>2013</year>) <volume>35</volume>(<issue>4</issue>):<fpage>331</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1179/1743132812Y.0000000144</pub-id><pub-id pub-id-type="pmid">23336676</pub-id></mixed-citation>
</ref>
<ref id="B98">
<label>98</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermans</surname><given-names>MC</given-names></name><name><surname>Faber</surname><given-names>CG</given-names></name><name><surname>Vanhoutte</surname><given-names>EK</given-names></name><name><surname>Bakkers</surname><given-names>M</given-names></name><name><surname>De Baets</surname><given-names>MH</given-names></name><name><surname>de Die-Smulders</surname><given-names>CE</given-names></name><etal></etal></person-group>
<article-title>Peripheral neuropathy in myotonic dystrophy type 1</article-title>. <source/>J Peripher Nerv Syst (<year>2011</year>) <volume>16</volume>(<issue>1</issue>):<fpage>24</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1111/j.1529-8027.2011.00313.x</pub-id><pub-id pub-id-type="pmid">21504499</pub-id></mixed-citation>
</ref>
<ref id="B99">
<label>99</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>OK</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>BJ</given-names></name></person-group>. <article-title>Abnormalities of nerve conduction studies in myotonic dystrophy type 1: primary involvement of nerves or incidental coexistence?</article-title>
<source/>J Clin Neurosci (<year>2008</year>) <volume>15</volume>(<issue>10</issue>):<fpage>1120</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1016/j.jocn.2007.11.002</pub-id><pub-id pub-id-type="pmid">18657426</pub-id></mixed-citation>
</ref>
<ref id="B100">
<label>100</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harper</surname><given-names>PS</given-names></name><name><surname>Dyken</surname><given-names>PR</given-names></name></person-group>
<article-title>Early-onset dystrophia myotonica. Evidence supporting a maternal environmental factor</article-title>. <source/>Lancet (<year>1972</year>) <volume>2</volume>(<issue>7767</issue>):<fpage>53</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1016/S0140-6736(72)91548-6</pub-id><pub-id pub-id-type="pmid">4113301</pub-id></mixed-citation>
</ref>
<ref id="B101">
<label>101</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeesman</surname><given-names>S</given-names></name><name><surname>Carson</surname><given-names>N</given-names></name><name><surname>Whelan</surname><given-names>DT</given-names></name></person-group>. <article-title>Paternal transmission of the congenital form of myotonic dystrophy type 1: a new case and review of the literature</article-title>. <source/>Am J Med Genet (<year>2002</year>) <volume>107</volume>(<issue>3</issue>):<fpage>222</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1002/ajmg.10141</pub-id><pub-id pub-id-type="pmid">11807903</pub-id></mixed-citation>
</ref>
<ref id="B102">
<label>102</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angeard</surname><given-names>N</given-names></name><name><surname>Gargiulo</surname><given-names>M</given-names></name><name><surname>Jacquette</surname><given-names>A</given-names></name><name><surname>Radvanyi</surname><given-names>H</given-names></name><name><surname>Eymard</surname><given-names>B</given-names></name><name><surname>Heron</surname><given-names>D</given-names></name></person-group>. <article-title>Cognitive profile in childhood myotonic dystrophy type 1: is there a global impairment?</article-title>
<source/>Neuromuscul Disord (<year>2007</year>) <volume>17</volume>(<issue>6</issue>):<fpage>451</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.nmd.2007.02.012</pub-id><pub-id pub-id-type="pmid">17433680</pub-id></mixed-citation>
</ref>
<ref id="B103">
<label>103</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallgren-Pettersson</surname><given-names>C</given-names></name><name><surname>Bushby</surname><given-names>K</given-names></name><name><surname>Mellies</surname><given-names>U</given-names></name><name><surname>Simonds</surname><given-names>A</given-names></name></person-group>
<article-title>117th ENMC workshop: ventilatory support in congenital neuromuscular disorders – congenital myopathies, congenital muscular dystrophies, congenital myotonic dystrophy and SMA (II) 4-6 April 2003, Naarden, The Netherlands</article-title>. <source/>Neuromuscul Disord (<year>2004</year>) <volume>14</volume>(<issue>1</issue>):<fpage>56</fpage>–<lpage>69</lpage>.<pub-id pub-id-type="doi">10.1016/j.nmd.2003.09.003</pub-id><pub-id pub-id-type="pmid">14659414</pub-id></mixed-citation>
</ref>
<ref id="B104">
<label>104</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathieu</surname><given-names>J</given-names></name><name><surname>Allard</surname><given-names>P</given-names></name><name><surname>Potvin</surname><given-names>L</given-names></name><name><surname>Prevost</surname><given-names>C</given-names></name><name><surname>Begin</surname><given-names>P</given-names></name></person-group>. <article-title>A 10-year study of mortality in a cohort of patients with myotonic dystrophy</article-title>. <source/>Neurology (<year>1999</year>) <volume>52</volume>(<issue>8</issue>):<fpage>1658</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1212/WNL.52.8.1658</pub-id><pub-id pub-id-type="pmid">10331695</pub-id></mixed-citation>
</ref>
<ref id="B105">
<label>105</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekstrom</surname><given-names>AB</given-names></name><name><surname>Hakenas-Plate</surname><given-names>L</given-names></name><name><surname>Samuelsson</surname><given-names>L</given-names></name><name><surname>Tulinius</surname><given-names>M</given-names></name><name><surname>Wentz</surname><given-names>E</given-names></name></person-group>. <article-title>Autism spectrum conditions in myotonic dystrophy type 1: a study on 57 individuals with congenital and childhood forms</article-title>. <source/>Am J Med Genet B Neuropsychiatr Genet (<year>2008</year>) <volume>147B</volume>(<issue>6</issue>):<fpage>918</fpage>–<lpage>26</lpage>.<pub-id pub-id-type="doi">10.1002/ajmg.b.30698</pub-id><pub-id pub-id-type="pmid">18228241</pub-id></mixed-citation>
</ref>
<ref id="B106">
<label>106</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douniol</surname><given-names>M</given-names></name><name><surname>Jacquette</surname><given-names>A</given-names></name><name><surname>Guile</surname><given-names>JM</given-names></name><name><surname>Tanguy</surname><given-names>ML</given-names></name><name><surname>Angeard</surname><given-names>N</given-names></name><name><surname>Heron</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>Psychiatric and cognitive phenotype in children and adolescents with myotonic dystrophy</article-title>. <source/>Eur Child Adolesc Psychiatry (<year>2009</year>) <volume>18</volume>(<issue>12</issue>):<fpage>705</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="doi">10.1007/s00787-009-0037-4</pub-id><pub-id pub-id-type="pmid">19543792</pub-id></mixed-citation>
</ref>
<ref id="B107">
<label>107</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douniol</surname><given-names>M</given-names></name><name><surname>Jacquette</surname><given-names>A</given-names></name><name><surname>Cohen</surname><given-names>D</given-names></name><name><surname>Bodeau</surname><given-names>N</given-names></name><name><surname>Rachidi</surname><given-names>L</given-names></name><name><surname>Angeard</surname><given-names>N</given-names></name><etal></etal></person-group>
<article-title>Psychiatric and cognitive phenotype of childhood myotonic dystrophy type 1</article-title>. <source/>Dev Med Child Neurol (<year>2012</year>) <volume>54</volume>(<issue>10</issue>):<fpage>905</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="doi">10.1111/j.1469-8749.2012.04379.x</pub-id><pub-id pub-id-type="pmid">22861906</pub-id></mixed-citation>
</ref>
<ref id="B108">
<label>108</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schara</surname><given-names>U</given-names></name><name><surname>Schoser</surname><given-names>BG</given-names></name></person-group>. <article-title>Myotonic dystrophies type 1 and 2: a summary on current aspects</article-title>. <source/>Semin Pediatr Neurol (<year>2006</year>) <volume>13</volume>(<issue>2</issue>):<fpage>71</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.spen.2006.06.002</pub-id><pub-id pub-id-type="pmid">17027856</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>